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Breast cancer is a serious public health issue, and a full understanding of its etiology and 
pathophysiology is a primary focus in the field. Molecularly, the combined action of a plethora 
of factors in multiple pathways is involved in the regulation of the breast tumoriogenic process. 
Characterization of a more complete spectrum of the molecular factors will provide insights into 
the development of new and improved diagnostic, prognostic and therapeutic tools for treating 
breast cancer. To this end, my studies utilize a combination of molecular biology and 
bioinformatic methods, to uncover the mechanisms underlying the regulation of gene expression 
and growth in human breast cancer cells. 
To investigate the molecular crosstalk of the estrogen and c-Jun N-terminal kinase 1 
(JNK1) signaling pathways, I monitored the genomic localization of estrogen receptor α (ERα) 
and JNK1 in basal and estrogen-stimulated MCF-7 breast cancer cells. I found that JNK1 binds 
to the promoter of many genes. ERα is required for the binding of JNK1 to the estrogen-induced 
sites, and JNK1 in turn functions as a coregulator of ERα. The convergence of ERα and JNK1 at 
target promoters regulates estrogen-dependent gene expression, as well as downstream estrogen-
dependent cell growth responses.  
Furthermore, the implication of long noncoding RNAs (lncRNAs) in breast cancer is also 
coming to light. I developed a computational approach that integrates information from multiple 

genomic datasets, and generated a comprehensive catalog of 1888 expressed lncRNA genes in 
MCF-7 cells. Almost half of them are first annotated in this study, and more than a quarter are 
estrogen-regulated. Close examination revealed many interesting features. Interestingly, cell 
type-specific expression of lncRNAs predicts the intrinsic molecular subtypes of breast cancer, 
suggesting its potential utility as prognostic marker. Lastly, by selecting lncRNAs with elevated 
expression in breast tumors, and whose differential expression across a wide spectrum of tissues 
and cell types correlates with important cell viability genes, we identified a number of lncRNAs 
that are required for the normal growth of human breast cancer cells.  
Collectively, my studies expanded our understanding of the molecular mechanisms 
underlying breast cancer biology, and suggested new targets for therapeutic interventions. 
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CHAPTER 1 
An Introduction to the Mechanisms Underlying the Regulation of 
Gene Expression and Growth of Breast Cancer Cells 
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1.1. Summary 
Extensive efforts have been undertaken to improve our understanding of breast cancer. 
We now know that the estrogen signaling pathway has established roles in the development of 
breast cancer, and its interplay with the growth factor signaling pathways has been associated 
with endocrine resistance in breast cancer. Moreover, the recent revelation of a large number of 
long noncoding RNAs (lncRNAs), has again introduced new players that are involved in the 
breast tumorigenic process. Clearly, breast cancer is a complex disease that involves the 
interplay of a wide variety of molecular factors. Therefore, my studies will aim to identify a 
more complete spectrum of such molecular factors, and to uncover molecular mechanisms 
underlying the regulation of gene expression and growth in breast cancer cells. 
 
1.2. Breast Cancer as a “Multi-Factorial” Disease 
Breast cancer is the most common form of cancer and the second leading cause of cancer 
death in American women. The estimated annual incidence of breast cancer worldwide is about 
one million cases (Dumitrescu and Cotarla 2005). Clearly, this is a serious public health issue, 
and efforts to understand the etiology and pathophysiology of the disease are essential. To this 
end, extensive efforts in breast cancer research has uncovered important aspects of the molecular 
basis of the disease, and has been instrumental in pushing forward significant medical advances 
in both breast cancer detection and treatment. We now know that breast cancer is a complex 
disease that manifests in many different forms, which often lead to different prognosis and 
responses to treatment options. At the molecular level, the combined action of a plethora of 
protein factors in multiple signaling pathways is involved in the regulation and fine-tuning of the 
breast tumoriogenic process. Identification and characterization of a more complete spectrum of 
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molecular factors at play will further our knowledge of breast cancer biology and provide 
insights into the development of new and improved diagnostic, prognostic and therapeutic tools 
for treating breast cancer. 
 
1.3. Estrogen Signaling Pathways in Breast Cancer 
Breast cancer presents itself as a classical model of hormone-dependent malignancy. It is 
well accepted that estrogens, the primary female sex hormone that play a central role in normal 
mammary gland development, are also pivotally involved in mammary tumoriogenesis as a 
result of their potent mitogenic effects (Manavathi, Dey et al. 2013). A prolonged or increased 
exposure to estrogens has been associated with an increased breast cancer risk (Pike, Gerkins et 
al. 1979; Begg, Kuller et al. 1987), while reduced exposure to estrogens results in the opposite 
effects (Hulka 1997). 
The molecular activities of estrogens are mediated through the estrogen receptor (ER) 
proteins, which consist of two isoforms, ERα (Greene, Gilna et al. 1986) and ERβ (Kuiper, 
Enmark et al. 1996), and belong to a conserved superfamily of nuclear receptor proteins that 
function as sequence-specific, DNA-binding transcription factors in the nucleus (Mangelsdorf, 
Thummel et al. 1995; Kininis, Chen et al. 2007). In the classical model (Fig. 1.1A), ERs 
dimerize upon ligand activation and bind directly to genomic DNA through estrogen response 
element (ERE) sequences (Kumar and Chambon 1988). In an alternative model (Fig. 1.1B), 
liganded ERs indirectly interact with genomic DNA through immediate transcription factors (e.g. 
NF-κB, Sp1 and AP-1), or tethering factors, via their recognition elements (Gaub, Bellard et al. 
1990; Weisz and Rosales 1990; Umayahara, Kawamori et al. 1994; Kushner, Agard et al. 2000). 
In both cases, a variety of cofactors including (1) histone modifying enzyme complexes that  
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Figure 1.1  Estrogen-dependent signaling pathways. 
 
Estrogen signaling pathways include: (A) “Classical”, the ligand-dependent binding of ER 
directly to the ERE; (B) “Non-Classical/Tethering”, the ligand-dependent binding of ER to 
DNA-bound transcription factors, the so-called tethering factors, and (C) “Extra-Nuclear”, the 
activation of kinase cascades by membrane-associated ER. 
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contain members of the steroid receptor coactivator family of proteins as the receptor binding 
subunit (Leo and Chen 2000),  (2) chromatin remodeling complexes such as SWI/SNF (Guyon, 
Narlikar et al. 1999; Robyr, Wolffe et al. 2000), and (3) Mediator complexes which contain 
Med220/TRAP220 as the primary receptor binding subunit (Malik and Roeder 2000; Rachez and 
Freedman 2001), act together with activated ERs to modify histones, alter chromatin structure, 
and regulate the recruitment and activity of RNA polymerase II (Pol II) transcriptional 
machinery (Fig. 1.2) (Wong, Lin et al. 2002). The interplay between ERs and these 
transcriptional cofactors leads to profound changes in the expression of estrogen-responsive 
genes that are associated with hormone-dependent physiological outcomes, such as in the case of 
promoting the development of breast cancer.  
About 2/3 of human breast cancers are ER-positive and likely to be estrogen-responsive 
at the time of diagnosis. Therefore, aromatase inhibitors that suppress estrogen production, and 
anti-estrogens that target ERs to antagonize the effects of estrogens, collectively known as the 
endocrine therapy, are often used clinically as first- and second-line treatment options for these 
early-stage breast cancers. Nevertheless, about half of these patients are tolerant or acquire 
resistance to endocrine therapy, and breast cancer remains a devastating disease. Additional 
factors and pathways are involved in breast cancer biology and we are clearly far away from 
gaining a full understanding. 
 
1.4. Interplay with the MAPK Signaling  Pathways  
In addition to the estrogen signaling pathway, components of the mitogen-activated 
protein kinases (MAPKs) pathways have also been implicated in hormone-dependent breast 
cancer(Smith 1998; Lange 2004). The MAPK pathways are mediated by the MAP kinases  
  6
 
 
 
Figure 1.2  ER-mediated activation of gene expression through collaboration with 
additional transcriptional coregulators. 
 
After binding estrogen, ER either dimerizes and binds to ERE (the classical pathway), or tethers 
to DNA-bound transcription factors (the non-classical, tethering pathway), where it then recruits 
a cohort of factors such as histone modifying proteins, chromatin remodeling proteins, and 
proteins associated with the basal transcriptional machinery. The classical pathway of ER-
mediated transcriptional activation is illustrated here as an example. 
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comprising the extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases 
(JNKs) and p38. They are activated by upstream kinases as extracellular signals such as the 
growth factors act through membrane-associated receptors to initiate a signaling cascade, and 
function to phosphorylate downstream effectors to control a variety of cellular processes such as 
cell proliferation and cell survival programs.  
There is a functional interplay between the estrogen and the MAPK signaling pathways. 
ERα is significantly phosphorylated at Serine-118, in response to either estrogen binding or 
activation of the MAPK pathway, and this phosphorylation influences the transactivation activity 
of ERα (Fig. 1.1C) (Lannigan 2003). The JNK family of MAPKs, as they are named, 
phosphorylate c-Jun at its N-terminus to modulate the activity of the ERα-associated 
transcription factor AP-1 (Fig. 1.1C) (Hibi, Lin et al. 1993; Dai, Rubie et al. 1995; Ip and Davis 
1998). Indeed, increased activity of the MAPK pathway is one of the hallmarks of more 
aggressive cancers and is often associated with the aforementioned hormone-refractory breast 
cancer. In these breast cancer cells, it is believed that the cellular physiology switches from ERα 
nuclear-initiated pathways to increased involvement of extra-nuclear-activated MAPK pathways 
(Sivaraman, Wang et al. 1997; Santen, Song et al. 2002; Hutcheson, Knowlden et al. 2003; 
Britton, Hutcheson et al. 2006; Jordan and O'Malley 2007; McGlynn, Kirkegaard et al. 2009).  
At the molecular level, ERα seems to be a possible point of convergence between the 
estrogen and MAPK signaling pathways in ERα-positive human breast cancer cells. In the 
absence of estrogens, ERα can be activated by growth factors such as the epidermal growth 
factor (EGF) and the insulin-like growth factors (IGFs) (Bunone, Briand et al. 1996; Ignar-
Trowbridge, Pimentel et al. 1996). EGF is known to stimulate signaling via the classical MAPK 
cascade, and hormone-refractory breast tumors are typically dependent on the overexpression of 
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EGF receptor (EGFR) and HER2, the membrane-associated receptors for EGF (Benz, Scott et al. 
1992; Pietras, Arboleda et al. 1995; Kurokawa, Lenferink et al. 2000; Nicholson, Hutcheson et 
al. 2001). Lupien and colleagues have demonstrated in their study that in MCF-7 cells, an ERα-
positive human breast cancer cell line, EGF signaling resulted in a unique set of ERα genomic 
targets, which is distinct from the estrogen-activated ERα cistrome but consistent with the 
molecular profiles of HER2-positive human breast cancer cells (Lupien, Meyer et al. 2010). 
Their findings suggested a molecular explanation for endocrine resistance as observed in a subset 
of ERα-positive breast cancers, and demonstrated an important role of growth factor/MAPK 
signaling in estrogen-responsive breast cancer cells.   
In addition, Madak-Erdogan and colleagues have shown that upon activation by the 
estrogens, ERK2 physically interacts with ERα and colocalizes with ERα at chromatin binding 
sites across the genome in MCF-7 breast cancer cells (Fig. 1.3) (Madak-Erdogan, Lupien et al. 
2011). This genomic colocalization leads to regulation of estrogen-dependent gene expression 
and cell proliferation programs (Fig. 1.3) (Madak-Erdogan, Lupien et al. 2011). Their results 
established a role of ERK2, a MAP kinase, as an ERα coregulator, which functions at gene 
promoters and distal enhancer to modulate the genomic actions of ERα, resulting in the 
regulation of transcriptional outcomes and cell growth responses. 
As mentioned earlier, JNK kinases are the other MAP kinases that are potentially 
involved in a functional crosstalk with the estrogen signaling pathway, due to their association 
with the ERα-associated tethering factor AP-1. Nevertheless, to what extent this functional 
crosstalk occurs and affects the physiology of estrogen-responsive breast cancer cells, and 
whether JNK kinases, such as JNK1, behave in a similar way as ERK2, is still unknown and will 
be addressed in Chapter 2 of my thesis. 
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Figure 1.3  ERK2 as an ER coregulator in regulating gene and proliferation programs. 
 
Model depicting the relationship between ERK2 and ERα in the hormonal regulation of gene 
expression and cell proliferation. Estrogen signaling leads to rapid activation of ERK2 (red star) 
and its colocalization with ERα at enhancer binding sites (and/or gene promoters). ERK2 
collaborate with ERα and a cohort of additional coactivators to regulate hormone stimulation of 
prolideration and cell cycle-related genes. The findings indicate that ERK2, and possibly other 
cellular kinases, not only possess a signaling function but also a nuclear role at chromatin in 
facilitating the estrogen/ER-dependent transcriptional regulation. Modified from Madak-
Erdogan, Lupien et al. 2011. 
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1.5. LncRNAs : A New Class of Regulators in Breast Cancer 
Traditionally, identification and characterization of important players in the regulation of 
gene expression and cellular outcomes in human breast cancer has been focused on proteins. 
Nevertheless, recent advances in high-throughput sequencing technologies have revealed that the 
genome is extensively transcribed, yielding a large repertoire of noncoding RNAs. This includes 
long noncoding RNAs, mRNA-like molecules that do not code for proteins, which are emerging 
as a new class of RNAs that have significant impact on almost all aspects of life. While the study 
of lncRNA function is still in its infancy, a role for a number of these transcripts has recently 
been established in cancer in general, and more specifically, in breast cancer.  
HOTAIR, for example, is one of the best-characterized lncRNAs to date. It is highly 
induced in metastatic breast cancer samples, and has been shown to be an independent predictor 
of breast cancer survival and metastasis-free survival (Gupta, Shah et al. 2010). Over-expression 
of HOTAIR in breast cancer cell lines results in increased cell invasion in vitro and metastasis in 
vivo (Gupta, Shah et al. 2010). In contrast to HOTAIR, which shows elevated expression in more 
aggressive breast cancers, the lncRNA GAS5 is expressed at reduced levels in tumors compared 
to unaffected breast epithelial tissues (Mourtada-Maarabouni, Pickard et al. 2009). Consistently, 
GAS5 expression induces growth arrest and apoptosis, and reduced expression of GAS5 in breast 
cancers is associated with a poorer prognosis (Mourtada-Maarabouni, Pickard et al. 2009). 
SRA is another example of an lncRNA that has been implicated in mammary 
carcinogenesis. It serves as a molecular scaffold that coordinates the functions of various 
transcription factors and coregulators, including ERα and its well-known coactivator SRC (Lanz, 
McKenna et al. 1999). Possibly through interacting and modulating the activity of ERα and its 
cofactors, SRA serves as a regulator of breast tumoriogenesis. In animal models, crossing SRA 
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transgenic mice with MMTV-ras mice, a model highly susceptible to the development of 
mammary tumors, reduces the incidence of mammary neoplasia (Lanz, Chua et al. 2003). In 
contrast, knockdown of SRA in MDA-MB-231 human mammary cancer cells, a model of 
invasive breast cancer with elevated expression of SRA, leads to reduced invasiveness (Foulds, 
Tsimelzon et al. 2010). Why reduced expression of SRA in one system and overexpression in 
another would both reduce aspects of cancer development and progression remains to be 
determined in future studies.   
The abovementioned examples represent individual lncRNAs that have been implicated 
in the initiation and progression of breast tumorigeneisis. Furthermore, transcriptome profiling 
using global nuclear run-on sequencing (GROseq, a method for mapping transcriptionally active 
RNA polymerases across the genome), has identified a large number of lncRNA-like transcripts 
in MCF-7 human breast cancer cells (Fig. 1.4) (Hah, Danko et al. 2011). About a quarter of these 
transcripts are regulated by 17β-estradiol (E2), and many of the E2-upregulated lncRNAs have 
ERα binding sites with their proximal promoter regions, suggesting a direct involvement of ERα 
in the regulation of their expression (Hah, Danko et al. 2011). It is reasonable to suggest that 
some of these transcripts are by definition lncRNAs, and could in turn regulate the estrogenic 
transcription programs, and possibly play a previously under-appreciated role in breast cancer 
biology. To this end, in the second part of my thesis, I will examine the extent of contribution of 
lncRNAs to the transcription outcome and cell proliferation programs in estrogen-responsive 
human breast caner cells, so as to ultimately explore the utility of functionally important 
lncRNAs in clinical applications to facilitate the treatment of breast cancer. 
 
1.6. Conclusions 
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Figure 1.4  Transcriptome profiling in MCF-7 cells using GROseq identified a large 
number of lncRNA-like transcripts. 
 
GROseq in MCF-7 cells across an E2 treatment time course of 0, 10, 40 and 160 min. captured 
the location and orientation of all actively transcribing RNA polymerases genome-wide. 
Transcription units were called de novo using a Hidden Markov Model-based statistical model. 
When the called transcripts are mapped to existing annotations, 10% of them correspond to loci 
of annotated lncRNA genes; while 47% of them are previously unannotated, some of them are 
likely unannotated lncRNA genes expressed in basal and E2-stimulated MCF-7 cells. About a 
quarter of all transcripts are E2-regulated, suggesting a previously underappreciated population 
of E2-regulated lncRNA genes in MCF-7 cells. Modified from Hah, Danko et al. 2011. 
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In conclusion, our molecular understanding of breast cancer is constantly expanding. It is 
accepted by now that breast cancer is a complex disease that integrates the activities of a plethora 
of molecular factors. Therefore, an improved understanding of a more complete spectrum of 
molecular factors and pathways that are involved in the breast tumorigenic process requires 
continual investigation, and is the focus of my studies in this dissertation thesis. 
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CHAPTER 2 
Estrogen Regulates JNK1 Genomic Localization to Control Gene 
Expression and Cell Growth in Breast Cancer Cells* 
 
 
 
 
 
 
 
 
 
 
 
* This work was published as Sun M, Isaacs GD, Hah N, Heldring N, Fogarty EA, Kraus WL. 
(2012). “Estrogen regulates JNK1 genomic localization to control gene expression and cell 
growth in breast cancer cells.” Mol Endocrinol. 26(5):736-47 © the Endocrine Society. Minor 
changes have been made. Isaacs GD contributed equally to this work (Fig. 2.1A-C, 2.6C, 2.7, 
2.8, 2.9B, 2.10-2.12); Heldring N assisted Isaacs GD in some of the experiments; Fogarty EA 
helped with ChIP-qPCR in Fig. 2.5B; and Hah N performed the proliferation assay in Fig. 2.9A. 
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2.1. Summary 
Steroid hormone and mitogen-activated protein kinase (MAPK) signaling pathways 
functionally intersect, but the molecular mechanisms of this crosstalk are unclear. Here we 
demonstrate a functional convergence of the estrogen and c-Jun N-terminal kinase 1 (JNK1) 
signaling pathways at the genomic level in breast cancer cells. We find that JNK1 binds to many 
promoters across the genome. Although most of the JNK1 binding sites are constitutive, a subset 
of are estrogen-regulated (either induced on inhibited). At the estrogen-induced sites, estrogen 
receptor alpha (ERα) is required for the binding of JNK1 by promoting its recruitment to 
estrogen response elements (EREs) or other classes of DNA elements through a tethering 
mechanism, which in some cases involves AP-1. At estrogen-regulated promoters, JNK1 
functions as a transcriptional coregulator of ERα in a manner that is dependent on its kinase 
activity. The convergence of ERα and JNK1 at target gene promoters regulates estrogen-
dependent gene expression outcomes, as well as downstream estrogen-dependent cell growth 
responses. Analysis of existing gene expression profiles from breast cancer biopsies suggests a 
role for functional interplay between ERα and JNK1 in the progression and clinical outcome of 
breast cancers. 
 
2.2. Introduction 
 Diverse signaling pathways regulate a wide variety of cellular processes in mammalian 
cells, including global transcription programs, to control both physiological and disease states 
(Kininis and Kraus 2008; Cheung and Kraus 2010).  The signaling pathways controlled by 
estrogens, such as the predominant natural form 17β-estradiol (E2), are good examples of the 
signal-dependent transcriptional control of cellular outcomes.   Estrogens bind to cognate nuclear 
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estrogen receptor proteins, ERα and ERβ, which function as sequence-specific, DNA-binding 
transcription factors in the nucleus to directly regulate the transcription of estrogen-responsive 
genes (Mangelsdorf, Thummel et al. 1995; Warner, Nilsson et al. 1999; Heldring, Pike et al. 
2007).  ERs bind directly to genomic DNA through ERE sequences (Kumar and Chambon 1988) 
or indirectly through other transcription factors (e.g., activating protein-1; AP-1) using a 
tethering mechanism (Gaub, Bellard et al. 1990; Weisz and Rosales 1990; Umayahara, 
Kawamori et al. 1994; Kushner, Agard et al. 2000; Kushner, Agard et al. 2000), where they 
recruit a variety of coregulator proteins that mediate transcriptional outcomes (Glass, Rose et al. 
1997; Acevedo and Kraus 2004).  The genes regulated by estrogens play key roles in the sexual 
development and fertility of both males and females (Hess 2003; Findlay, Liew et al. 2010), as 
well as the regulation of metabolic processes in fat, liver and bone tissues (Couse and Korach 
1999; Hewitt, Harrell et al. 2005; Li and Shen 2005; Murphy and Korach 2006; Pallottini, 
Bulzomi et al. 2008).  They also play important roles in the aberrant mitogenic and proliferative 
processes that underlie breast and uterine cancer (Prall, Rogan et al. 1998; Foster, Henley et al. 
2001; Sommer and Fuqua 2001).  In this regard, the expression of ERα in cells is a well-known 
prognostic indicator for breast cancers, and a variety of synthetic estrogen antagonists that target 
ERs are used as therapeutic agents for breast cancers to reverse the mitogenic actions of 
estrogens (Kuiper, van den Bemd et al. 1999; Johnston 2001; McDonnell, Chang et al. 2001).  
In contrast to the nuclear actions of estrogens, growth factors act through cytoplasmic 
membrane receptors to stimulate intracellular signaling pathways, including mitogen activated 
protein kinase cascades, which indirectly regulate gene expression through a variety of target 
transcription factors (Turjanski, Vaque et al. 2007).  The MAPK family comprises a conserved 
set of proteins that are activated by a series of upstream kinases that form a phosphorylation 
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relay.  Activated MAPKs, including the JNKs and the extracellular signal-regulated kinases 
(ERKs), phosphorylate downstream effectors at serine or threonine residues to control a variety 
of cellular processes (Davis 2000; Chang and Karin 2001; Johnson and Lapadat 2002; 
Vlahopoulos and Zoumpourlis 2004).  In addition to the direct stimulation of proliferation and 
cellular survival programs, growth factor signaling pathways functionally interact with estrogen 
signaling pathways to promote endocrine therapy-resistant growth of cancer cells.  Indeed, 
functional crosstalk between steroid hormone and growth factor/MAPK signaling pathways was 
demonstrated nearly two decades ago in steroid hormone-dependent cancers (Smith 1998; Lange 
2004), but our understanding of how these pathways converge at the genomic level to regulate 
gene expression remains incomplete. 
AP-1, which is a heterodimer of c-Jun and c-Fos or related transcription factors, functions 
as a terminal downstream target of MAPK pathways (Karin 1995; Hess, Angel et al. 2004).  The 
JNK family of MAPKs was first identified by its ability to specifically phosphorylate c-Jun to 
modulate the transcriptional activity of AP-1 (Hibi, Lin et al. 1993; Dai, Rubie et al. 1995; Ip and 
Davis 1998).  Subsequent studies have shown that JNK also phosphorylates and regulates the 
activity of other transcription factors, and non-transcription factors, in response to a variety of 
extracellular stimuli (Davis 2000; Vlahopoulos and Zoumpourlis 2004).  A number of previous 
studies have described considerable functional interplay between AP-1 and ERs (Webb, Lopez et 
al. 1995; Kushner, Agard et al. 2000; Teyssier, Belguise et al. 2001; Webb, Nguyen et al. 2003; 
Qi, Borowicz et al. 2004), including interactions at the level of chromatin through the 
aforementioned ER tethering pathway.  The extent to which JNK family members, such as 
JNK1, play a role in estrogen signaling pathways and where such potential functional 
interactions might occur in the cell has not been examined in detail.   
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The prevailing view in the literature has been that the kinase-mediated phosphorylation 
events regulating transcriptional outcomes do not occur at the genes that they ultimately regulate. 
Nonetheless, the terminal kinases of various signaling pathways are found in the nucleus under 
activating conditions (Edmunds and Mahadevan 2004; Turjanski, Vaque et al. 2007). In addition, 
gene-specific and genomic analyses in yeast (Pascual-Ahuir, Struhl et al. 2006; Pokholok, 
Zeitlinger et al. 2006), Drosophila (Suganuma, Mushegian et al. 2010), and mammalian cells 
(Bruna, Nicolas et al. 2003; Edmunds and Mahadevan 2004; Narayanan, Adigun et al. 2005; 
Vicent, Ballare et al. 2006; Dawson, Bannister et al. 2009; Hu, Xie et al. 2009; Bungard, Fuerth 
et al. 2010; Madak-Erdogan, Lupien et al. 2011) have shown that a number of signaling kinases 
bind to the promoters of genes whose expression they regulate.  For example, AMPK activates 
transcription in response to cellular stress through direct association with chromatin and 
phosphorylation of histone H2B at serine 36 (Bungard, Fuerth et al.).  Likewise, cyclin A/cdk2 is 
recruited to gene promoters where is functions as a progesterone receptor coactivator 
(Narayanan, Adigun et al. 2005).  In addition, ERK2 is recruited to ERα binding sites across the 
genome where it supports E2-induced gene expression (Madak-Erdogan, Lupien et al.).  The 
extent to which other transcription factors and other kinase families collaborate in the nucleus in 
a similar manner remains to be determined. 
In this study, we characterized the genomic relationships between ERα and JNK1 with 
respect to their binding to chromatin and subsequent transcriptional outcomes.  Our results 
support a model for the estrogen- and ERα-dependent recruitment of pre-activated JNK1 to the 
promoters of estrogen target genes.  JNK1, in turn, serves as a coregulator of ERα required for 
efficient estrogen-dependent transcription of these genes, and for downstream cell growth 
responses.  Our study has identified a genomic nexus between the estrogen and JNK1 signaling 
  23
pathways, and similar genomic systems are likely to integrate the signaling pathways for other 
steroid hormones and signal-regulated nuclear kinases in broader cellular processes. 
 
2.3. Results 
Activated/phosphorylated JNK1 localizes to the nuclei of MCF-7 cells  
 To explore the nuclear actions of JNK1 and its potential role in the estrogen signaling 
pathway, we used the ERα-positive MCF-7 human breast cancer cell line.  We first examined the 
extent to which JNK1 localizes to the nucleus in MCF-7 cells, and whether the natural ERα 
ligand E2 affects the activation (i.e., phosphorylation) and localization of JNK1.  Like other 
MAPKs, JNK1 is regulated by the phosphorylation of a Thr-Pro-Tyr motif by upstream MAPK 
kinases (Davis 2000; Turjanski, Vaque et al. 2007).  Phosphorylation of JNK1 promotes its 
translocation into the nucleus and activation of its enzymatic activity (Davis 2000; Turjanski, 
Vaque et al. 2007).   
 Fractionation of MCF-7 cells followed by Western blotting revealed that although JNK1 
is present in both the cytoplasm and nucleus, only the phosphorylated form of JNK1 is detected 
in the nucleus (Fig. 2.1A).  Treatment of the cells with E2 did not alter the localization of JNK1 
or the fraction of phosphorylated JNK1 (Fig. 2.1A). Immunofluorescent staining of the MCF-7 
cells confirmed that JNK1 is located in the cytoplasm and nucleus, and that E2 does not alter the 
localization of JNK1 (Fig. 2.1B).  The constitutive JNK1 phosphorylation may be the result of 
HER-2-dependent MAPK hyperactivation (Oh, Lorant et al. 2001), or it may be related to the 
elevated kinase activity associated with breast cancer cell lines (Santen, Song et al. 2002).  In 
either case, our results show that activated JNK1 is located in the nuclei of MCF-7 cells. 
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Figure 2.1  Estrogen signaling regulates JNK1 genomic localization program in MCF-7 
cells.  
 
(A) MCF-7 cells were treated with vehicle (U) or E2 (E) for 45 min. Cytoplasmic (Cyto) and 
nuclear (Nuc) extracts were made from both conditions and analyzed by Western blotting for 
JNK1 and phospho-JNK1. Arrows indicate the migration of phospho-JNK1. ERα was used as a 
control for cytoplasmic and nuclear fractionation, and GAPDH was used as a loading control. 
 
(B) Immunofluorescent staining of JNK1 (red signal) in MCF-7 cells before and after E2 
treatment.  One of the nuclei in each panel is denoted by a white dotted line. 
 
(C) Analysis of promoter-proximal JNK1-binding sites in MCF-7 cells before and after E2 
treatment by ChIP-chip using Nimblegen promoter arrays containing approximately 19,000 
unique promoters tiled from 2200 bp upstream to 500 bp downstream of the TSS (arrow).  The 
data are shown as heatmaps of the JNK1 ChIP-chip log2 enrichment ratios in both treatment 
conditions for all promoters with significant binding in either condition, and for 0.5% of JNK1-
absent promoters.  They are shown in categories of released, constitutive, recruited and absent 
based on the fold changes of ChIP-chip signals between the E and U conditions.  The promoters 
in each category are aligned by their positions relative to the TSS and ordered from those with 
the 5’-most JNK1 peak to those with the 3’-most JNK1 peak.  
 
(D) Peak-centered averaging graphs (metagene analyses) of the log2 enrichment ratios from 
regions in the categories shown in (C). The probe signals are centered on JNK1 peaks and 
averaged for all promoters across the region from -2 kb to + 2 kb relative to the JNK1 peak. 
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Estrogen signaling regulates the JNK1 genomic localization program in MCF-7 cells  
 Based on previous studies showing that a number of signaling kinases associate with 
chromatin, we considered the possibility that nuclear JNK1 may also associate with chromatin in 
MCF-7 cells. Furthermore, even though E2 treatment did not alter the subcellular distribution of 
JNK1, we also considered the possibility that E2 might alter the genomic localization of JNK1.  
To address these questions, we determined the genomic localization of JNK1 at all annotated 
promoters across the MCF-7 cell genome using chromatin immunoprecipitation coupled with 
hybridization to RefSeq promoter microarrays (i.e., ChIP-chip) with arrays spanning 
approximately -2 kb to +0.5 kb relative to the transcription start site. The ChIP DNA was 
prepared from MCF-7 cells treated with (“E”) or without (“U”) 100 nM E2.    
 Using stringent peak definition criteria, we identified more than 500 promoters with a 
significant peak of JNK1 in either treatment condition (~2% of all promoters on the array) (Fig. 
2.1C). Gene-specific ChIP-qPCR of peak and non-peak regions confirmed the ChIP-chip results 
(Fig. 2.2). Interestingly, E2 treatment caused a redistribution of the JNK1 localization pattern, 
with 141 peaks changing upon E2 treatment. Thirty-five promoters showed a release of JNK1 
upon E2 treatment and 106 promoters showed a recruitment of JNK1 upon E2 treatment, while 
the majority of JNK1-bound promoters (367) were unaffected by E2 treatment (i.e., 
constitutively bound by JNK1) (Fig. 2.1C). Averaging of JNK1 peak centered ChIP-chip data 
across these classes illustrates the distinct patterns of JNK1 promoter binding in response to E2 
(Fig. 2.1D). These data show that JNK1 localizes to discrete genomic binding sites and that E2 
regulates the JNK1 genomic localization program. Together with the data in Figs. 2.1A and 
2.1B, we conclude that E2 treatment alters the occupancy of activated JNK1 on gene promoters 
in MCF-7 cells without altering the overall nuclear pool of JNK1. 
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Figure 2.2 Confirmation of JNK1 and ERα  peaks from the ChIP-chip analysis by ChIP-
qPCR.  
 
ChIP-qPCR was performed to determine JNK1 (left) and ERα (right) occupancy at significantly 
bound (Significant; Sig) and unbound (Un) regions as defined by the ChIP-chip analyses shown 
in Figs. 1 and 2.  The relative enrichment of each qPCR amplicon tested is shown in the cluster 
plot, grouped by whether or not the region of the amplicon is bound by JNK1 or ERα based on 
ChIP-chip peak definition.  Red bars represent the average signal in each group.  Significant 
JNK1- and ERα-bound regions from the ChIP-chip analyses show enrichment of factor binding 
compared to the unbound regions in the ChIP-qPCR experiments, confirming the ChIP-chip 
analysis. 
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Gene ontology (GO) analyses showed that JNK1 binding is enriched in the promoters of 
genes that code for proteins involved in responses to stimuli, signal transduction, and RNA 
splicing (Table 2.1). These GO categories are driven largely by the group of genes with JNK1 
constitutively bound at the promoter. A separate analysis of the genes associated with the JNK1-
released and JNK1-recruited promoters also showed an enrichment of genes that code for 
proteins involved in transcriptional regulation and metabolism of steroids (Table 2.1). Together, 
these results point to a role for JNK1 in cell growth responses, much like those observed in 
response to the mitogenic actions of estrogens. 
 
E2-recruited JNK1 colocalizes with ERα at many target promoters 
 Given the estrogen-dependent alterations in the JNK1 genomic localization program, we 
tested the possibility that some JNK1 peaks might correspond to sites of ERα binding. To do so, 
we performed an ERα ChIP-chip analysis using the same array platform that we used for the 
JNK1 ChIP-chip in Fig. 2.1. Of the 508 significant peaks of JNK1 binding that we identified in 
the three groups (i.e., released, constitutive, and recruited), ~15% overlapped with an ERα 
binding site. This increased dramatically to ~40% of the significant peaks of JNK1 when the 
analysis was limited to the 106 promoters with E2-induced binding of JNK1, suggesting the 
existence of two populations of E2-induced JNK1 binding sites: ERα-positive (~40%) and ERα-
negative (~60%; based on significant peaks). 
 More broadly, correlation analysis of these 106 promoters showed a striking positive 
correlation between JNK1 and ERα binding (Fig. 2.3, A and B; Pearson correlation coefficient of 
0.68).  This analysis, which is more inclusive than the direct peak-to-peak comparison described 
above because it considers all detectable ChIP-chip signals regardless of significance, suggests
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 Table 2.1  Gene ontology analysis of JNK1-bound promoters. 
 
a Ontologies were obtained using Genecodis for the (1) All JNK1-bound, (2) JNK1-released, (3) 
JNK1-constitutive, and (4) JNK1-recruited genes.  The entire gene list represented on the ChIP-
chip array was used as the background reference.  GO terms representing less than 5 genes were 
not considered.   
 
b p-values were determined by Genecodis using Chi-square tests.  Randomized gene lists of 
equal size to each gene set analyzed were generated from the genes present on the ChIP-chip 
array to determine a significance threshold and demonstrate the specificity of ontology 
assignments.   
 
c Five random gene sets were generated using the programming language R from the total 
number of genes present on the ChIP-chip array.  No GO terms were enriched (i.e., all p-values 
were >0.001) in the random lists using the criteria described above. 
Gene set Ontologya p-valueb 
   
All JNK1-bound promoters • Response to stimulus  1.99 x10-12 
 • Signal transduction  3.02 x10-10 
 • GPCR signaling pathway 1.64 x10-8 
 • RNA splicing 3.22 x10-8 
   
JNK1-released promoters • Regulation of transcription 7.67 x10-4 
   
JNK1-constitutive promoters • Response to stimulus  5.44 x10-11 
 • GPCR signaling pathway 1.07 x10-8 
 • Signal transduction 1.51 x10-6 
 • RNA splicing 8.30 x10-6 
   
JNK1-recruited promoters •  Regulation of transcription, DNA- 
      dependent 
3.65 x10-7 
 • Response to drugs 1.22 x10-6 
 • Signal transduction 1.71 x10-5 
 • Metabolism of androgens and  
      estrogens 
6.0 x10-6 
   
Five random gene setsc • None <0.001 
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Figure 2.3  JNK1 recruitment correlates with ERα  occupancy at target promoters in MCF-
7 cells. 
 
(A) Analysis of promoter-proximal JNK1 and ERα binding in MCF-7 cells.  JNK1 and ERα 
ChIP-chip data from E2-treated MCF-7 cells for the 106 “JNK1-recruited” promoters from Fig. 
1C are shown as heatmaps of log2 recruitment ratios aligned and ordered as in Fig. 1C.  
 
(B) Pearson correlation analysis of the JNK1 and ERα ChIP-chip log2 recruitment ratios. 
 
(C) Metagene analyses of the log2 enrichment ratios of JNK1 (top) and ERα (bottom) ChIP-chip 
data for the “JNK1-recruited” promoters from Fig. 1C before (U, in blue) and after (E, in red) E2 
treatment.  The probe signals are centered on the JNK1 peaks in both the JNK1 and ERα graphs.  
 
(D and E) ChIP-chip (left) and ChIP-qPCR (right) analyses of JNK1 and ERα at two “JNK1-
recruited” gene promoter regions (PCYT1A in panel D and CYP1B1 in panel E) in MCF-7 cells 
treated with vehicle (U) or E2 (E).  The average JNK1 ChIP-qPCR signals (right) of peak 
regions defined by ChIP-chip (gray boxes in left panels) are consistent with the array profiles.  
For the ChIP-qPCR analyses, each bar represents the mean + SEM, n = 3. 
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that there may be even greater colocalization of JNK1 and ERα binding.  This result is further 
illustrated by (1) averaging ERα ChIP-chip signals centered on the E2-recruited JNK1 peaks 
(Fig. 2.3C) and (2) examining JNK1 and ERα ChIP signals from ChIP-chip and ChIP-qPCR data 
for the promoters of two target genes (PCYT1A and CYP1B1; Figs. 2.3D and 2.3E, respectively).  
These analyses show a pattern of ERα promoter binding that is induced in response to E2, much 
like JNK1 binding, suggesting that JNK1 and ERα are co-recruited to these genomic binding 
sites.   
 To confirm that JNK1 and ERα are present simultaneously at these binding sites, we 
performed ChIP-reChIP experiments for a selected set of JNK1-bound promoters (JNK1-
recruited and constitutive).  Whether we first immunoprecipitated ERα (Fig. 2.4A, top) or JNK1 
(Fig. 2.4B, top), we were able to detect both proteins in the reChIP for three JNK1-recruited 
promoters (GREB1, CYP1B1, and PCYT1A; Fig. 2.4, bottom).  In contrast, ERα did not show 
strong binding to the JNK1 constitutively-bound promoter, ACO2, and we were thus unable to 
reChIP JNK1 at this promoter, as expected (Fig. 2.4A, bottom).  These results demonstrate that, 
for these promoters, E2-recruited JNK1 co-occupies its binding sites with ERα, indicating that 
E2 signaling causes the convergence of ERα and JNK1 pathways. 
 
E2-dependent binding of JNK1 to many target promoters is dependent on ERα 
 Co-recruitment of JNK1 and ERα to specific sites in the genome following E2 treatment 
suggests a role for ERα in mediating the E2-induced genomic localization of JNK1 at these sites.  
To explore the dependency of E2-dependent JNK1 recruitment to genomic binding sites on ERα, 
we used small interfering RNAs (siRNAs) to knock down ERα in MCF-7 cells.  A pool of ERα- 
targeting siRNAs, but not a control pool, effectively depleted ERα in the cells (Fig. 2.5A, left,
  33
 
 
 
 
Figure 2.4 JNK1 and ERα  colocalize at promoters of “JNK1-recruited” genes. 
 
(A and B) ChIP-qPCR (top) and reChIP-qPCR (bottom) was performed reciprocally for ERα 
and JNK1 for three “JNK1-recruited” gene promoters (GREB1, CYP1B1, and PCYT1A) and one 
“JNK1-consititutive” gene promoter (ACO2).  The initial ChIP (top) was performed using 
antibodies to ERα (A) or JNK1 (B).  The recovered ChIP DNA was then immunopreciptated 
using antibodies to JNK1 (A) or ERα (B) in a reChIP experiment (bottom).   The ChIP and 
reChIP DNAs were analyzed by RT-qPCR.   Each bar represents the mean + SEM, n = 3. 
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Figure 2.5  ERα  binding at target promoters is required for JNK1 recruitment.  
 
(A) MCF-7 cells were transfected with control or ERα siRNAs.  Sixty hours after transfection, 
the cells were treated with vehicle (U) or E2 (E) for 45 min. and collected for Western blotting or 
ChIP-qPCR analyses.  ChIP-qPCR analyses of the E2-dependent JNK1 (left) and ERα (right) 
binding to three “JNK1-recruited” gene promoters (TFF1, CYP1B1, and PCYT1A) and one 
“JNK1-constitutive” gene promoter (ACO2) are shown.  Each bar represents the mean + SEM, n 
= 3. (Inset in left panel) Western blot analysis of siRNA-mediated ERα knockdown versus 
control (“C”).  β-actin was used as a loading control.  
 
(B) ChIP-qPCR analyses of E2-dependent JNK1 (left) and ERα (right) binding to four gene 
promoters (PCYT2, DPP4, LAMB2, and ORMDL3) in parental HeLa cells and HeLa cells stably 
expressing ERα (HeLa-ERα).  The cells were treated with vehicle (U) or E2 (E) for 45 min and 
analyzed by ChIP-qPCR.  Each bar represents the mean + SEM, n = 3. 
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inset).  As shown in Fig. 2.5A, it also blocked E2-dependent recruitment of ERα (left) and JNK1 
(right) to target gene promoters (e.g., TFF1, CYP1B1, PCYT1A).  In contrast, depletion of ERα 
did not affect the localization of JNK1 to the constitutive JNK1-bound promoter of ACO2 (Fig. 
2.5A). 
 To further explore the dependency of E2-dependent JNK1 recruitment on ERα, we used 
HeLa cells lacking (i.e., HeLa) or stably expressing (i.e., HeLa-ERα) ERα.  Using these two cell 
lines, we examined the promoter localization of ERα and JNK1 in response to E2 treatment.  
While no promoter localization of ERα or JNK was observed in the ERα-negative HeLa cells, 
E2-induced ERα and JNK1 recruitment was observed at specific gene promoters in the HeLa-
ERα cells (Fig. 2.5B), consistent with the results from the MCF-7 cells.  Together, these 
experiments using two different strategies show definitively that functionally active ERα is 
required for the E2-dependent recruitment of JNK1 to target promoters where they co-localize.  
 
Transcription factor binding sites are found under JNK1 peaks 
 As noted above, ERα exhibits two distinct modes of genomic binding: (1) direct binding 
to genomic DNA through EREs (Heldring, Pike et al. 2007) or indirect binding through other 
transcription factors (e.g., AP-1) using a tethering mechanism (Kushner, Agard et al. 2000).  To 
determine which mode of binding might direct the co-recruitment of ERα and JNK1, we 
employed a series of bioinformatic analyses.  First, we used MEME and MAST in an unbiased 
search for DNA sequence motifs enriched under the JNK1 peaks in E2-treated condition.  These 
results yielded a number of high confidence motifs (Fig. 2.6A and Table 2.2).  Using TESS to 
predict the transcription factors that might bind to these sequences, we identified AP-1, as well 
as other transcription factors not previously associated with ERα-dependent gene regulation
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Figure 2.6  Motif analysis of JNK1 peaks. 
(A) Unbiased search for DNA sequence motifs enriched under the JNK1-bound regions in the 
E2-treated condition using MEME.  A selection of some of the most significantly enriched 
motifs are shown as web logos of the position weight matrices.  Motif predictions were examined 
by TESS, as well visual inspection, to determine transcription factors that are most likely to bind 
to the indicated sequence, as indicated. 
 
(B) Targeted search for AP-1 and ERα (i.e., ERE) binding motifs (1) under all JNK1 peaks in 
both vehicle- and E2-treated conditions, (2) JNK1 peaks in the E2-treated condition, and (3) 
under all JNK1-recruited peaks.  (Top) The position weight matrices used in the targeted search 
for AP-1 and ERα binding motifs are shown as web logos.  The AP-1 position weight matrix is 
from TRANSFAC., whereas  the ERα position weight matrix is based on information from 
O’Lone et al. (O'Lone, Frith et al. 2004).  (Bottom) The position weight matrices for the AP-1 
and ERα motifs were used with MAST to map the location of the motifs under JNK1 peaks in a 
directed search.  The percent of JNK1 binding sites in each of the indicated groups with an AP-1 
or ERα motifs motif is shown.  
 
(C) c-Fos localizes with JNK1 and ERα at target promoters containing an AP-1 binding motif.  
ChIP-qPCR analyses of JNK1, ERα, and c-Fos binding at JNK1- and ERα-recruited regions 
before (U) and after estrogen (E) treatment.  The UGT2B15, SPTBN4, TFF1, and GREB1 gene 
promoters contain at least one predicted AP-1 motif under the JNK1 peak.  The TFF1, GREB1, 
and PLAC1 promoters, as well as the BLK44 distal enhancer (Carroll, Liu et al. 2005), contain at 
least one ERE under the JNK1 peak.  Each bar represents the mean + SEM, n = 3. 
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Table 2.2  Unbiased motif analysis of JNK1 peaks. 
 
 
Sequencea, b 
No. of sitesc 
(No. of windows)d 
 
p-valuee 
 
TESS callf 
 
IDg 
JNK1 - E peaks     
GCCTGTAAGTCCCAGC 50 (38) 3.24E-06 Bcd Q00016 
AGGCTGAGGCAGGAG 50 (36) 1.09E-07 AP-1 - 
TGTTGCCCAGGCTGG 50 (40) 1.50E-12 ½ ERE R04883 
GAGGTTGCAGTGAGC 47 (43) 1.16E-08 – - 
GCCACCACGCCCGGC 50 (36) 1.27E-03 Sp1 R01702 
TAGAGACGGGGTTTC 50 (38) 8.02E-20 SIF R02244 
CTTGAGCCCAGGAGT 50 (37) 1.13E-10 LBP-1 I00191 
GATCGTGCCACTGCA 38 (35) 7.24E-04 NF-1/L R01322 
CACCTCAGCCTCCCA 19 (18) 8.10E-07 Sp1 R02245 
TGAATGAATAAATA 44 (38) 7.70E-82 POU1F1a R00623 
GCACAGCTTCCCTGC 19 (10) 3.96E-28 Sp1 R08166 
CTCGAACTCCTGACC 22 (22) 3.71E-15 AP-1 R00368 
   ½ ERE I00276 
JNK1-recruited     
GCCTGTAATCCCAGC 43 (27) 1.74E-14 Bcd Q00016 
CTGCCTCAGCCTCCC 50 (23) 9.99E-16 Sp1 R02245 
TGTTGCCCAGGCTGG 43 (25) 3.06E-10 ½ ERE R04883 
GCCACCACGCCCGGC 36 (22) 1.24E-04 Sp1 R01702 
GAAACCCCGTCTCTA 32 (23) 3.06E-10 SIF R02244 
GAGGATCACTTGAGC 47 (31) 7.36E-11 IRF-2 R00917 
CAGTGAGCTGAGATC 22 (20) 6.12E-10 Zeste R04948 
AGTGCAGTGGC 18 (17) 3.88E-16 Sp1 R01021 
 
a Unbiased search for DNA sequence motifs enriched under the JNK1-bound regions using 
MEME.  De novo motif predictions were performed for: (1) all promoters showing JNK1 
binding at in the E2-treated condition (“JNK1 - E peaks”) or (2) promoters showing JNK1 
recruitment upon E2 treatment (“JNK1-recruited”).  The gene lists were formulated using the 
tools on the Galaxy browser (Elnitski, King et al. 2006) so genomic locations from JNK1-bound 
regions would not be present in the background regions.  De novo motif detection was carried 
out using MEME (Bailey, Williams et al. 2006) on repeat-masked sequences.  MAST (Motif 
Alignment and Search Tool) (Bailey, Williams et al. 2006) was used to scan for the locations of 
all motif instances within both bound and unbound sequences, using a p-value threshold of 1.5 x 
10-4 (Bailey, Williams et al. 2006).  Fisher’s exact tests were used to determine enrichments 
relative to background, with p-values corrected for multiple testing using the Holm method in R.  
 
b The sequences are listed 5’ to 3’. 
 
c Number of times each motif listed was identified in the promoter regions of the genes in each 
category (i.e., “JNK1 - E peaks” or “JNK1-recruited”). 
 
(continued on the next page) 
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Table 2.2.  (continued) 
 
d The number of peak-containing windows in which the sequence is found.  Note that two or 
more sites may be in one peak-containing window. 
  
e p-value generated by a Fisher exact test. 
 
f The transcription factor binding site associated with the sequence, as called by TESS (Schug 
2008).  TESS was used to predict the transcription factors that might bind to the enriched 
sequences from MEME.  Position weight matrices for the predicted transcription factors were 
obtained from the TRANSFAC database (Wingender, Chen et al. 2001).  Adjusted matrices for 
the predicted transcription factors were mapped to the JNK1-bound and JNK1-negative regions 
with MAST using a 6th order Markov model.  Fisher's exact tests were used to determine the 
enrichments for each motif.  
 
g The ID from TESS, IMD (information matrix database) ID for each transcription factor. 
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(e.g., the POU homeodomain transcription factor POU1F1/PIT1; Fig. 2.6A).  Of note, the motifs 
did not include a canonical ERE, but did include an ERE half-site. 
 Next, in a directed search, we mapped probability weight matrices (obtained from 
TRANSFAC) for AP-1 and ERα binding motifs to the JNK1 peaks.  Although full EREs were 
not identified in the unbiased search, we included the ERE probability weight matrix in this 
directed search based on our results showing a role for ERα in the E2-dependent recruitment of 
JNK1 to promoters.  This analysis yielded high confidence sites for the AP-1 and ERα binding 
motifs (Fig. 2.6B, top).  For all groups tested, we observed a greater enrichment of ERα binding 
motifs (i.e., EREs) than AP-1 binding motifs (Fig. 2.6B, bottom).  These results of these 
bioinformatic analyses, together with the ChIP-chip results described above, suggest that the E2-
dependent recruitment of JNK1 occurs through ERα using both (1) direct binding to EREs and 
(2) a tethering mechanism mediated by AP-1 and possibly other DNA-binding transcription 
factors. 
 We tested the validity of our bioinformatics analyses using gene-specific ChIP-qPCR 
assays.  For this analysis, we focused on JNK1-recruited promoters (and one ERα enhancer, 
BLK44; (Carroll, Liu et al. 2005)) containing high confidence AP-1 motifs or EREs.  Although 
these JNK1-recruited genomic regions showed E2-induced binding of JNK1 and ERα, as 
expected, only those with a high confidence AP-1 motif showed binding of c-Fos, a component 
of the AP-1 heterodimer (Fig. 2.6C).  Interestingly, the binding of c-Fos was also stimulated by 
E2 treatment (Fig. 2.6C, bottom), as we have reported previously (Heldring, Isaacs et al. 2011), 
suggesting E2-induced binding of a complex containing ERα, AP-1, and JNK1 at target 
promoters.  Together, these results support the validity of our bioinformatic analyses by 
demonstrating the recruitment of JNK1 and c-Fos to regions containing predicted AP-1 sites. 
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JNK1 acts as an ERα  coregulator at E2-responsive genes 
 Next, we determined the role of JNK1 in the E2-dependent expression of target genes in 
MCF-7 cells using reverse transcription-qPCR (RT-qPCR) coupled with knockdown of JNK1 or 
chemical inhibition of JNK1 kinase activity.  As shown in Fig. 2.7A, stable expression of a short 
hairpin RNA (shRNA) into the cells resulted in efficient knockdown of both JNK1 mRNA (top) 
and protein (bottom).  As expected, this also resulted in reduced occupancy of JNK1 at the 
promoters of estrogen-regulated genes (Fig. 2.8).  Knockdown of JNK1 (Fig. 2.7B) or chemical 
inhibition of JNK catalytic activity using SP600125 (Fig. 2.7C) inhibited the E2-stimulated 
expression of some, but not all, estrogen target genes.  Furthermore, the results with JNK1 
knockdown were consistent with those from the JNK inhibitor (Fig. 2.7, B and C).  Thus, JNK1 
protein and its kinase activity are required for full E2-dependent regulation of estrogen target 
genes in MCF-7 cells, implicating JNK1 as a hormone-dependent transcriptional coregulator of 
ERα.  
 
JNK1 is required for E2-dependent growth of MCF-7 cells  
 E2 regulates the transcription of estrogen-responsive genes, including a set of genes 
involved in cell growth control (Kininis and Kraus 2008). This transcriptional program underlies 
the potent mitogenic effects of E2 on estrogen-responsive cells, such as MCF-7 cells.  To 
determine the role JNK1 in E2-dependent mitogenic responses, we determined the proliferation 
of MCF-7 cells in response to E2 treatment with or without JNK1 knockdown.  Two different 
shRNAs targeting JNK1, expressed individually in the cells, reduced the E2-dependent 
proliferation of MCF-7 cells by about half (Fig. 2.9A).  These results suggest that the impaired 
E2-dependent transcriptional responses that we observed upon JNK1 knockdown (Fig. 2.7B) are
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Figure 2.7  JNK1 activity is required for full estrogen-dependent transcriptional responses 
at estrogen target promoters.  
 
(A) JNK1 was stably knocked down in MCF-7 cells by retroviral-mediated delivery of an 
shRNA construct followed by drug selection.  An shRNA construct targeting GFP was used as a 
control.  (Top) Analysis of JNK1 mRNA expression by RT-qPCR.  β-actin mRNA was used as 
an internal control.  Each bar represents the mean + SEM, n = 3.  (Bottom) Analysis of JNK1 
protein levels by Western blotting.  β-actin was used as a loading control.  
 
(B) Effect of JNK1 knockdown on estrogen-dependent gene expression.  The E2-regulated 
expression of four JNK1-recruited genes (GREB1, PLAC1, ELOVL2, and HOXC10) in control 
(GFP) and JNK1 knockdown MCF-7 cells was monitored by RT-qPCR before (U) and after (E) 
a 3-hour treatment with E2.  Each bar represents the mean + SEM, n = 3.  Asterisks represent p-
values: <0.05 (∗) or <0.01 (∗∗) (Student’s t-test versus corresponding E2 control). 
 
(C) Effect of inhibiting JNK catalytic activity on estrogen-dependent gene expression.  The E2-
regulated expression of the four JNK1-recruited genes shown in (B) were examined by RT-
qPCR in the absence or presence of the JNK inhibitor SP600125 (SP) for 2 hours, before a 3-
hour treatment with vehicle (U) or E2 (E).  Each bar represents the mean + SEM, n = 3.  
Asterisks represent p-values: <0.05 (∗) or <0.01 (∗∗) (Student’s t-test versus corresponding E2 
control). 
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Figure 2.8  Loss of JNK1 occupancy at target gene promoters in JNK1 knockdown cells.  
 
JNK1 was stably knocked down in MCF-7 cells by retroviral-mediated delivery of an shRNA 
targeting JNK1 into the cells, followed by drug selection.  Knockdown of JNK1 mRNA and 
protein was confirmed as shown in Fig. 6A.  ChIP-qPCR using a JNK1 antibody was performed 
in JNK1 knockdown and control (GFP shRNA) cell lines in the absence (U) and presence (E) of 
E2 treatment for the four “JNK1-recruited” gene promoters shown (TFF1, GREB1, SPTBN4, and 
HOXC10).  The results demonstrate a reduction of E2-induced JNK1 binding at gene promoters 
upon JNK1 knockdown, as expected.  
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Figure 2.9  JNK1 is required for full estrogen-dependent growth responses in MCF-7 cells. 
 
(A) Analysis of E2-dependent cell growth in control (GFP) and JNK1 knockdown MCF-7 cells 
grown for 10 days in the absence (U) or presence (E) of E2.  Two independent JNK1 shRNA 
(KD1 and KD2) constructs were used, as shown, and the number of cells in each condition was 
counted every two days.  Each point represents the mean ± SEM, n = 3.  
 
(B) JNK1 expression is elevated in breast carcinomas.  Data obtained from gene expression 
analyses were analyzed using Oncomine.  The relative expression of MAPK8 (i.e., JNK1) from 4 
normal breast stroma samples and 51 breast tumor samples is shown.  The Oncomine-reported p-
value was <3.0 x 10-4.  The values were normalized to an average expression level of 1 for the 
normal breast samples.  Red lines represent the average signal in each category. 
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reflected in a corresponding loss of cell growth (Fig. 2.9A).   
 The observed link between JNK1 and estrogen signaling may have relevance for the 
growth and clinical outcomes of estrogen-dependent breast cancers.  In this regard, note that the 
expression of JNK1 is upregulated in breast cancers (Fig. 2.9B).  In addition, the expression of 
the JNK1 phosphatase, MPK-1, a negative regulator of JNK1 activity, is reduced in high grade 
malignant breast cancers (Fig. 2.10).  Both of these cancer-related changes would increase the 
net JNK1 activity and, hence, have the potential to modulate estrogen-dependent growth 
responses in those cells. 
 
2.4. Discussion 
 Our genomic and gene-specific analyses of the nuclear functions of JNK1 have revealed 
new facets of JNK1 biology, including functional interplay with the estrogen signaling pathway.  
Collectively, our results indicate that (1) activated nuclear JNK1 binds to specific sites in the 
genome (Fig. 2.1), (2) E2 induces a redistribution of JNK1 binding at promoters (Fig. 2.1), (3) 
E2-induced binding of JNK1 at many target genes is mediated by the E2-induced formation of 
promoter-bound complexes containing ERα and, in some cases, tethering proteins such as AP-1 
(Figs. 2.2 through 2.6), (4) JNK1 can act as a coregulator of ERα-dependent transcriptional 
outcomes (Fig. 2.7), and (5) the estrogen and JNK1 signaling pathways collaborate to control the 
proliferation of breast cancer cells (Fig. 2.9).  Thus, the functional interplay between the estrogen 
and MAPK signaling pathways that has been observed previously is manifested in a molecular 
crosstalk at the genomic level.  These results help to define the molecular mechanisms 
underlying estrogen signaling in the nucleus and estrogen-dependent gene regulation. 
Our results support a model for the estrogen- and ERα-dependent recruitment of pre-
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Figure 2.10  Expression of the JNK phosphatase, MKP-1, decreases with breast cancer 
progression.  
 
Data obtained from the Oncomine database were plotted as shown.  The relative expression of 
MKP-1 across three breast carcinoma grades is shown from five independent studies (indicated 
by the last names of the first authors).  The p-values for negative correlation were <0.001 for all 
five studies.  The values were normalized so that the average expression level for the Grade 1 
sample from each study was 1.  Red bars represent the average signal in each category. 
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activated JNK1 from the nuclear compartment (i.e., nucleoplasm or chromatin) to the promoters 
of estrogen target genes. JNK1, in turn, serves a coregulator function required for efficient 
estrogen-dependent transcription of these genes.  This role of JNK1 in the genomic estrogen 
signaling pathway is supported by JNK1's kinase activity, which likely targets histones or other 
proteins in the promoter-assembled transcription complexes, as described for other cellular 
kinases in the nucleus (Baek 2011). Indeed, two well-characterized ERα coregulators, p300 and 
SRC1, are strongly phosphorylated by JNK1 in vitro, whereas ERα is only weakly 
phosphorylated (Fig. 2.11). Nucleosomal histone H3 is also phosphorylated by JNK1, but only 
when JNK1 is recruited to the nucleosomes by a DNA-bound transcription factor, such as AP-1 
(Fig. 2.12). Determining the functional relevance of these and other potential targets of JNK1 
will be an important question to address in future studies. 
 Our results fit well with the growing evidence supporting a role for cellular kinases in the 
nucleus and across the genome (Baek 2011). A recent study by Madak-Erdogan et al. showed 
that ERK2 is recruited to ERα binding sites across the genome, where it supports E2-induced 
gene expression (Madak-Erdogan, Lupien et al.). There are a number of parallels between this 
study and ours, which suggests that there may be some universal features for cellular kinase 
actions across the genome, at least in the estrogen signaling pathway. These include the 
following: (1) estrogen-induced binding and colocalization of the kinase and ERα at specific 
sites in the genome, (2) a requirement for ERα to drive the recruitment of the kinase to 
chromatin, (3) interplay with other transcription factors (e.g., AP-1 for JNK1 and CREB1 for 
ERK2), possibly through a tethering mechanism, (4) a requirement for the kinase to be activated 
and (5) a role for the kinase in estrogen-dependent gene regulation. The extent to which these 
features apply to other kinases and other transcription factors, especially other nuclear receptors,  
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Figure 2.11  JNK1 phosphorylates ERα  coactivators in vitro.  
 
(A) Activated recombinant JNK1 was expressed in bacteria, purified as described previously 
(Khokhlatchev, Xu et al. 1997), and analyzed by SDS-PAGE with staining using Coomassie 
Brilliant Blue. 
 
(B) In vitro kinase assays using recombinant JNK1.  JNK1 was incubated with ERα, p300, or 
SRC1 in the presence of 32P-ATP, and phosphorylation of the target proteins was detected by 
autoradiography.  p300 was strongly phosphorylated by JNK1 (note the relative exposure times 
for each autoradiogram).  
 
(C) p300 and SRC-1, but not ERα, contain a putative JNK interaction domain, similar to the 
JNK-interacting sequence in c-Jun.  Key:  + = basic amino acid; x = any amino acid; T = 
Threonine; Φ = hydrophobic amino acid; R = Arginine; K = Lysine; M = Methionine; V = 
Valine. Numbers represent the first amino acid position in the motif. 
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Figure 2.12  JNK1 phosphorylates nucleosomal histone H3 in vitro.  
 
Kinase reactions were performed using recombinant JNK1, as shown in Fig. S3A.  JNK1 was 
incubated with core histones or an equivalent amount of core histones assembled into 
mononucleosomes containing an AP-1 binding site by salt dialysis.  The nucleosome reactions 
were performed in the absence or presence of recombinant AP-1 (c-Fos/c-Jun heterodimers) to 
target JNK1 specifically to the nucleosome.  32P phosphorylation of histones, c-Fos, and c-Jun 
was detected by autoradiography. Nucleosomal H3 is a target of JNK1 enzymatic activity when 
JNK1 is specifically targeted to the nucleosome. 
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remains to be determined.  
 In summary, our studies have identified significant molecular crosstalk between the 
estrogen and JNK1 signaling pathways that regulates target gene expression and downstream cell 
growth responses. As noted above, similar genomic systems are likely to integrate the signaling 
pathways for other steroid hormones and signal-regulated nuclear kinases. 
 
2.5. Methods and Materials 
Cell culture and treatments.  MCF-7 cells were maintained in MEM with Hank’s salts (Sigma; 
M1018) supplemented with 5% calf serum.  Prior to all experimental procedures and treatments, 
the cells were grown for at least 3 days in phenol red-free MEM Eagle medium with Earle's salts 
(Sigma; M3024) supplemented with 5% charcoal-dextran-treated calf serum, as described 
previously (Kininis, Chen et al. 2007).  Adherent HeLa and HeLa-ERα cells were maintained in 
DMEM/F12 (Sigma, D2906) supplemented with 10% charcoal-dextran stripped calf serum, as 
described previously (Heldring, Isaacs et al. 2011).  The cells were treated with control vehicle 
(ethanol) or E2 (100 nM) for the times specified in the figure legends.  For the JNK inhibition 
experiments, the cells were pre-treated with control vehicle or 20 μM SP600125 (SP; Biomol) 
for 1 hour before treatment with E2. 
 
Antibodies.  The antibodies used were as follows: JNK1 (Santa Cruz, sc-474), pan-JNK (Santa 
Cruz, sc-7345), phosphorylated pan-JNK (Santa Cruz, sc-6254), ERα (rabbit polyclonal 
generated in the Kraus lab), and c-Fos (rabbit polyclonal generated in the Kraus lab). 
 
JNK1 subcellular localization.  Estrogen-starved MCF-7 cells were treated with ethanol or 100 
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nM E2 for 45 min. and then fractionated into cytoplasmic and nuclear extracts in the presence of 
phosphatase inhibitors (5 mM NaF, 1 mM sodium vanadate).  The extracts were subjected to 
immunoblotting using antibodies against JNK1, phosphorylated JNK1, ERα, and GAPDH. 
 
Immunofluorescent staining of cells for JNK1.  Estrogen-starved MCF-7 cells were grown on 
coverslips and treated with ethanol or 100 nM E2 for 45 min.  The cells were fixed with 3% 
formaldehyde, permeabilized with 0.1% Triton X-100, blocked with 5% BSA, and subjected to 
staining with primary (anti-JNK1) and secondary (fluorescein-conjugated anti-goat IgG) 
antibodies.  The coverslips were then washed 5 times with TBST, mounted on slides using 
Vectashield (Vector Laboratories; H-1000), and visualized using a Leica Confocal Microscope 
System. 
 
Chromatin immunoprecipitation (ChIP).  ChIP assays for JNK1, ERα, and c-Fos were 
performed using a ChIP protocol described previously (Kininis, Chen et al. 2007), with minor 
modifications.  The key difference in the protocol was the inclusion of a crosslinking step with 
10 mM dimethyl suberimidate•HCl (DMS; Pierce, 20700) for 10 min. at room temperature prior 
to crosslinking with 1% formaldehyde for 10 min at 37°C.  The ChIP DNA was dissolved in 
water and analyzed by qPCR using a set of gene-specific primers.  Each ChIP experiment was 
conducted with at least three independent chromatin isolates to ensure reproducibility. 
 
ChIP-reChIP.  Following the primary ChIP, JNK1- and ERα-precipitated complexes were 
eluted with 10 mM DTT twice for 20 min at 37°C.  Eluates were diluted 20 times in ChIP 
dilution buffer, incubated with a second antibody at 4°C overnight, followed by the addition of 
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the protein-A/G-agarose bead mixture.  After this secondary ChIP, washing, elution, reversal of 
the crosslinks and analysis by qPCR were carried out as described for the standard ChIP protocol 
described above.  
 
ChIP-chip.  JNK1- and ERα-precipitated genomic DNA was blunted, amplified by LM-PCR, 
and labeled as described previously (Krishnakumar, Gamble et al. 2008).  The labeled samples 
were combined and hybridized to human HG18 RefSeq Promoter Arrays (Nimblegen; C4226-
00-01), which contain ~19,000 well-characterized RefSeq promoters tiled with 50-mer to 75-mer 
probes every 100 bp.  The tiled regions cover ~2200 bp upstream and ~500 bp downstream of 
each TSS. The ChIP-chip experiments were performed using three independent ChIP DNA 
isolates from cells treated with or without E2. 
 
ChIP-chip data analysis.  Data processing was done essentially as described previously 
(Krishnakumar, Gamble et al. 2008) using the statistical programming language R (Harrow, 
Denoeud et al. 2006), All R scripts are available upon request.  The analysis included three 
components: (1) a moving window analysis using a 1000 bp moving window with 250 bp steps 
in which both the mean probe log2 ratio and p-value from a nonparametric Wilcoxon signed-rank 
test were calculated for each window, (2) definition of regions with significant JNK1 or ERα 
binding or significant fold changes in JNK1 or ERα binding according to a set of definitions and 
criteria elaborated in Supplemental Materials, and (3) visual representation of the data by 
generating TSS-anchored heat maps using Java Treeview (Saldanha 2004).  The ChIP-chip data 
have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO 
Series accession number GSE13200 
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(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13200).  
 
Knockdown of ERα  and JNK1 in MCF-7 cells.  Transient RNAi-mediated knockdown of ERα 
was performed using transient transfection of siRNAs purchased from Dharmacon with an 
appropriate control siRNA pool.  The control or ERα siRNAs pools were transfected into MCF-7 
cells as recommended by Dharmacon.  Sixty hours after transfection, the cells were treated with 
E2 and collected for experiments.  Stable RNAi-mediated knockdown of JNK1 was performed 
using retroviral-mediated gene transfer of short hairpin RNA (shRNA) sequences specifically 
targeting the JNK1 mRNA with the pSUPER.retro system under appropriate drug selection 
(Oligoengine).  The JNK1 target sequences are as follows:  
5’-CAGAGAGCTAGTTCTTATGAA-3’ and 5’-CCTACAGAGAGCTAGTTCTTA-3’.  As a 
control, we used an shRNA sequence directed against GFP.  Knockdown was verified by 
immunoblotting and RT-qPCR. 
 
Gene-specific expression analyses by RT-qPCR.  The expression of endogenous target genes 
was determined by reverse transcription-quantitative PCR (RT-qPCR), as described previously 
(Kininis, Chen et al. 2007), with minor modifications.  The cDNA products form the reverse 
transcription reactions were analyzed by qPCR using a set of gene-specific primers.  Each 
experiment was conducted with at least three independent RNA isolates to ensure 
reproducibility. 
 
Bioinformatic analyses. De novo motif predictions were performed on gene lists that show 
JNK1 binding at their promoters in the E2-treated condition. These lists were formulated using 
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the tools on the Galaxy browser (Elnitski, King et al. 2006) so genomic locations from JNK1-
bound regions would not be present in the background regions.  De novo motif detection was 
carried out using MEME (Multiple Em for Motif Elicitation) (Bailey, Williams et al. 2006) on 
repeat-masked sequences.  The top 20 motifs in each peak class were retained for further 
analysis.  MAST (Motif Alignment and Search Tool) (Bailey, Williams et al. 2006) was used to 
scan for the locations of all motif instances within both bound and unbound sequences, using a p-
value threshold of 1.5 x 10-4, as previously reported (Bailey, Williams et al. 2006).  Fisher’s 
exact tests were used to determine enrichments relative to background with p-values corrected 
for multiple testing using the Holm method in R.  
TESS (Transcription Element Search Software) (Schug 2008) was used to predict the 
transcription factors that might bind to the enriched sequences from MEME.  Position weight 
matrices for the predicted transcription factors were obtained from the TRANSFAC database 
(Wingender, Chen et al. 2001).  Adjusted matrices for the predicted transcription factors were 
mapped to the JNK1-bound and JNK1-negative regions with MAST using a 6th order Markov 
model.  Fisher's exact tests were used to determine the enrichments for each motif, as described 
above.  In addition, promoters were scanned for the presence of EREs in the same manner and 
the enrichment was calculated. 
 
Gene ontology (GO) analyses.  Gene ontologies were obtained using Genecodis (Nogales-
Cadenas, Carmona-Saez et al. 2009) for the “All JNK1-bound”, “JNK1-released”, “JNK1-
constitutive”,  and “JNK1-recruited” gene sets.  The entire gene list represented on the ChIP-chip 
array was used as the background reference.  GO terms representing less than 5 genes were not 
considered.  p-values were determined by Genecodis using Chi-square tests.  Randomized gene 
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lists (of equal size to each gene set analyzed) were generated from the genes present on the 
ChIP-chip array to determine a significance threshold and demonstrate the specificity of 
ontology assignments.  Five random gene sets were generated using the programming language 
R from the total number of genes present on the ChIP-chip array.  No GO terms were enriched 
(i.e., all p-values were >0.001) in the random lists using the criteria described above. 
 
In vitro kinase assays.  Kinase reactions were conducted using recombinant JNK1 purified from 
E. coli using an activated MAP kinase purification system kindly provided by Dr. Melanie Cobb 
(University of Texas Southwestern Medical Center at Dallas) and described previously 
(Khokhlatchev, Xu et al. 1997) with two major modifications: (1) the human JNK1 cDNA 
(JNK1α1) was cloned in to replace the rat JNK2 cDNA sequence and (2) the final cation 
exchange purification was omitted.  Purified activated JNK1 (300 nM) was incubated with 
various substrates for 30 min. at 30°C in kinase buffer (25 mM HEPES pH 7.5, 10 mM 
magnesium acetate, 50 μM ATP, 2 μCi γ-32P-ATP).  The labeled proteins were resolved using 
SDS-polyacrylamide gel electrophoresis, the gels were dried on filter paper, and the 32P signal 
was detected using a phosphorimager system.  The substrates tested were as follows: core 
histones from HeLa cells (140 ng), salt-dialyzed mononucleosomes with an AP-1 binding site 
containing approximately 140 ng of HeLa cell core histones assembled as described (Jeong, 
Lauderdale et al. 1991), FLAG-tagged SRC1 (160 nM) purified as described (Thackray and 
Nordeen 2002), FLAG-tagged ERα (160 nM) and 6xHis-tagged p300 (160 nM) purified as 
described (Kraus, Manning et al. 1999), and c-Fos/c-Jun dimers (300 nm) purified as described 
(Ferguson and Goodrich 2001). 
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Primers for qPCR. The following oligonucleotide primers were used for the ChIP-qPCR and 
RT-qPCR assays. 
 
ChIP-qPCR: 
ACO2 forward 5’- CTTGCACCAGGCCCGTCT-3’ 
ACO2 reverse 5’- AAGATGTTTTACCCAAGAACAAAT - 3’ 
Blk44 forward 5’- GGGAAAATATGCAGAAGAAAACGA -3’ 
Blk44 reverse 5’- CATTTATTCAACACCTCTGATGTCCTA -3’ 
CYP1B1 forward 5’- CGTGCGGCCTCGATTG -3’ 
CYP1B1 reverse 5’- AGGTGCCCACGTTTCCATT -3’ 
GREB1 forward 5’- AGTGTGGCAACTGGGTCATTCTGA -3’ 
GREB1 reverse 5’- GGTATGATTCATCATTGTCTGCTGCG -3’ 
PCYT1A forward 5’- CCCTCGCTGTCACTTACCA -3’ 
PCYT1A reverse 5’- GTTGCAGGTGTGTGCCTATC -3’ 
PLAC1 forward 5’- TGACAGAACTCATTCACAGGAAG -3’ 
PLAC1 reverse 5’- GGCAACAGCAAGCACTACAA -3’ 
SPTBN4 forward 5’- GACTACACGTGCGTGACACC -3’ 
SPTBN4 reverse 5’- ACGTCCCACACCCTATCGTA -3’ 
TFF1 forward 5’- ATAACATTTGCCTAAGGAGGCCCG -3’ 
TFF1 reverse  5’- TCAGCCAAGATGACCTCACCACAT -3’ 
UGT2B15 forward 5’- TGAACTGTACACACTAATTGGTGAGTCA -3’ 
UGT2B15 reverse 5’- TCGTGGTGCAAGTAATGTCTTCTAA -3’ 
 
  57
RT-qPCR: 
ACTB forward 5’- AGCTACGAGCTGCCTGAC -3 
ACTB reverse 5’- AAGGTAGTTTCGTGGATGC -3’ 
GREB1 forward 5’- GCCGTTGACAAGAGGTTC -3’ 
GREB1 reverse 5’- GGGTTGAGTGGTCAGTTTC -3’ 
ELOVL2 forward 5’- AGAGGGTGGTTCATGTTGGA -3’ 
ELOVL2 reverse 5’- CAAGGTGAGGATACCCCTGA -3’ 
HOXC10 forward 5’- GACACCTCGGATAACGAAGC -3’ 
HOXC10 reverse 5’- TTTCTCCAATTCCAGCGTCT -3’ 
PLAC1 forward 5’- CAGTGAGCACAAAGCCACAT -3’ 
PLAC1 reverse 5’- AACCACAGGAAACAGGAAGC -3’ 
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CHAPTER 3 
Integrative Annotation and Functional Characterization of Long 
Noncoding RNAs in Human Breast Cancer Cells* 
 
 
 
 
 
 
 
 
 
 
 
* This research was done with contributions from Gadad SS.. He assisted with the generation of 
RNA-seq libraries, carried out siRNA-mediated knockdown of the two candidate lncRNAs, and 
performed the corresponding cell proliferation assay. 
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3.1. Summary 
Long noncoding RNAs (lncRNAs) that are emerging as key regulators in a wide variety 
of cellular processes, including breast cancer, but the extent of their implications is just 
beginning to be elucidated. Therefore, I developed a computational approach that integrates 
information from multiple high-throughput sequencing datasets, and derived at a comprehensive 
catalog of 1888 expressed lncRNA genes in the estrogen-responsive MCF-7 breast cancer cells. 
More than 40% of them are first annotated in this study. Close examination of these lncRNAs 
revealed many interesting features, including their distribution along the genome, their 
subcellular localization and the associated stability, as well as their chromatin signatures. More 
than a quarter of these lncRNAs are regulated by estrogen, either transcriptionally or post-
transcriptionally. In addition, cell type-specific expression of lncRNAs predicts the instrinsic 
molecular subtypes of breast cancer cells, suggesting its potential utility as prognostic marker. 
Lastly, by selecting lncRNAs with elevated expression in breast tumors, and whose differential 
expression across a whole spectrum of tissues and cell types correlates with important cell 
viability genes, we identified a number of lncRNAs that are required for the normal growth of 
MCF-7 cells. Collectively, these results expanded our knowledge in the implications of lncRNAs 
in breast cancer biology, and suggested new targets for therapeutic interventions. 
 
3.2. Introduction 
Genome-wide transcriptome analyses conducted over the past decade, including recent 
studies by the ENCODE (Encyclopedia of DNA Elements) Consortium, have revealed that 
mammalian genomes are pervasively, but not indiscriminately, transcribed, giving rise to a wide 
variety of coding and non-coding RNA (ncRNA) transcripts (Okazaki, Furuno et al. 2002; 
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Birney, Stamatoyannopoulos et al. 2007; Djebali, Davis et al. 2012). The cellular repertoire of 
non-coding RNAs consists of small housekeeping RNAs such as ribosomal RNAs (rRNAs) and 
transfer RNAs (tRNAs), microRNAs, and long noncoding RNAs (lncRNAs) including antisense 
RNAs (asRNAs) and enhancer RNAs (eRNAs).  The functions of many of these ncRNAs are 
poorly understood, but interests in uncovering their biological functions and molecular 
mechanisms of action are intense.  In this review, we focus on lncRNAs, presenting the most 
current information on their discovery, annotation, molecular actions, and biological functions, 
especially as they relate to hormonal signaling systems. 
 
3.2.1. Defining lncRNAs 
 lncRNAs, defined as non-protein coding RNA transcripts longer than 200 nucleotides 
(nt), are emerging as key regulators of diverse cellular processes.  To date, a limited, but fast 
growing number of lncRNAs have been functionally characterized through gene-specific studies. 
To further expand our understanding of lncRNAs, rapid advancements in genomic methods and 
analyses have spearheaded recent efforts in the large-scale identification of lncRNAs across 
multiple biological systems.  Nevertheless, accurate identification demands a clear definition and 
sufficient knowledge of the features of lncRNAs.  
 
3.2.1.1. An Evolving Definition of LncRNAs 
 The definition of lncRNAs continues to evolve.  A universal classification scheme does 
not exist, and there have been various synonyms describing either very similar or slightly 
differing lncRNA-like molecules, adding to the confusion.  The basic features are represented in 
the name “lncRNA”: they are obligate “non-coding” RNAs  (Fig. 3.2.1, top) and are relatively  
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Figure 3.2.1  Definition and key features of lncRNAs. 
 
Graphical representation of the definition and key features of lncRNAs, including the length of 
mature cDNA > 200 nt, the lack of coding capability, being mostly transcribed by RNA Pol II, 
spliced, 5’-capped and 3’-polyadenylated, and displaying a variety of gene location and 
orientation relative to a protein-coding gene. 
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“long” (>200 nt) (Fig. 3.2.1, top).  Some definitions include an “intergenic” feature (i.e., 
“lincRNAs”; by definition, they do not overlap in any way with annotated protein coding 
transcription units) (Guttman, Amit et al. 2009; Khalil, Guttman et al. 2009; Guttman, Garber et 
al. 2010; Cabili, Trapnell et al. 2011).   
 Length.  While the current pool of known lncRNAs display a wide range of transcript 
length, the lower bound for “long” is somewhat arbitrarily set to be greater than 200 nt in an 
attempt to facilitate distinction from most other well-characterized groups of small ncRNA 
trancripts, such as rRNAs, tRNAs, small nuclear RNAs (snRNAs), small nucleolar RNAs 
(snoRNAs), and microRNAs.  This length was chosen for practical considerations as well, since 
this threshold allows empirical separation of RNAs in common experimental procedures.  The 
200 nt cutoff, however, does not make clear biological distinctions, creating potential grey areas 
in our understanding.  
 Coding potential.  The absolute requirement for “noncoding” also invites controversy.  
Recent results from ribosome profiling studies have shown that some previously classified 
lncRNAs are detected in association with ribosomes.  To some, such results would preclude 
these transcripts from consideration as lncRNAs, since they are likely to be translated and, 
therefore, coding.  It raises the question of whether protein-coding capacity completely prevents 
an RNA transcript from being defined as a lncRNA.  Some RNAs may function both as a 
structural RNA and a coding RNA (see the steroid receptor RNA activator below; SRA).  The 
SRA gene produces a functional ncRNA, as well as a protein-coding variant(Lanz, McKenna et 
al. 1999; Chooniedass-Kothari, Emberley et al. 2004; Chooniedass-Kothari, Hamedani et al. 
2006).  Although the SRA gene fails to satisfy the definition of “noncoding”, we can still argue 
this is a case where the functional lncRNA isoform can be unambiguously distinguished from its 
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coding isoforms.  Nevertheless, cases of functional lncRNA-like transcripts with a detectable 
level of coding potential have been described.  Their protein-coding capability can be 
reminiscent of degenerate evolution as the noncoding function prevails, or the RNA transcript 
can simply be bifunctional, being both a protein-coding RNA and a functional lncRNA.  Instead 
of excluding any lncRNA-like transcripts due to a potential to code for a polypeptide product, a 
more reasonable approach may be to use a definition of “noncoding” that focuses on a coding-
independent functional role of the untranslated RNA transcript.  Thus, the key feature of is a 
lncRNA must function as a RNA transcript, whether or not it also codes for a polypeptide. 
 Transcription and processing.  In many respects, lncRNAs resemble protein-coding 
mRNAs: mostly spliced, and polyadenylated RNA polymerase II (Pol II) transcripts (Fig. 3.2.1, 
top).  Also, although not explicitly tested in most cases, lncRNAs are thought to be 5’-capped 
like mRNAs (Fig. 3.2.1, top).  Pol II is more likely to be responsible for these long RNA 
transcripts due to its higher processivity, and RNA Pols I and III are generally limited to the 
transcription of short housekeeping RNA transcripts.  The polyadenylation of lncRNAs is 
consistent with transcription by Pol II, and it helps to stabilize the transcripts to preserve their 
functional roles.  Nonetheless, non-polyadenylated, Pol III-transcribed, noncoding RNA 
transcripts, such as BC200(Mus, Hof et al. 2007), and asOct4-pg5(Hawkins and Morris 2010), 
have been identified.  Both are functional RNAs, playing roles in the regulation of translation 
and chromatin structure respectively, and are commonly referred to as lncRNAs in the literature.  
While BC200 is 200 nt long, barely fulfilling the minimum length requirement of lncRNAs, the 
actual length of asOct4-pg5 has not been evaluated and may be even shorter than 200 nt.  Thus, 
the notion that Pol I and Pol III transcripts are too short too meet the criteria of a lncRNA still 
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holds true; BC200 may just be a rare exception that marginally escapes the arbitrary length 
cutoff. 
 Gene location and orientation.  Historically, the focus has been on those lncRNAs 
encoded by genes that are well separated from genes encoding known protein-coding transcripts, 
hence the name “long intergenic noncoding RNAs (lincRNAs),” as noted above(Guttman, Amit 
et al. 2009; Khalil, Guttman et al. 2009; Guttman, Garber et al. 2010; Cabili, Trapnell et al. 
2011).  Nonetheless, as discovered in the large-scale discovery efforts noted below, “genic” 
lncRNAs are emerging as a prevalent class, with approximately one third to one half of lncRNAs 
overlapping protein-coding genes(Jia, Osak et al. 2010; Derrien, Johnson et al. 2012).  They can 
be further divided into (1) natural antisense transcripts (NATs) (Zhang, Liu et al. 2006; Li, 
Zhang et al. 2008), which run in the opposite direction to known mRNA genes and overlap with 
their gene bodies either in the exonic or intronic regions, (2) divergent lncRNAs, which originate 
from the opposite DNA strand, but use the same promoters as mRNAs, extending in the opposite 
direction, and (3) promoter-associated lncRNAs and 3’-UTR-associated lncRNAs, grouped 
based on their proximal location relative to the start and end of mRNAs genes (Fig. 3.2.1, 
bottom). Various hypotheses have linked each of these classes of lncRNAs to a specific mode of 
action, but the extent to which gene location and molecular function is associated, and whether 
such location-based classification holds real biological meaning, still remains to be determined.  
 
3.2.1.2. A Working Definition of LncRNAs 
As illustrated here, questions remain regarding a unifying definition for lncRNAs.  The 
field, however, has reached the point of having a solid working definition for lncRNAs.  For the 
purpose of convenience and simplicity in identifying lncRNAs and distinguishing them from 
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other major classes of RNA transcripts, RNA molecules longer than 200 nt and having little 
coding potential are often classified as lncRNAs.  They are very likely transcribed by Pol II, and 
in many cases, are capped, spliced, and polyadenylated. 
 
3.2.2. Identifying and Cataloging lncRNAs 
 The earliest efforts to identify lncRNAs were mostly gene-specific, starting with the 
discovery of a novel transcript associated with a specific biological function and followed by the 
surprising realization that the function of the transcript is independent of the production of a 
protein product.  More recently, significant advances in high-throughput sequencing technology 
and bioinformatics have revolutionized non-coding RNA discovery.  In recent studies, the 
combined use of genomic and bioinformatic approaches have led to the large-scale identification 
of a whole host of novel lncRNAs.  Consistent with the definition of lncRNAs, the general 
strategy involves two major steps: (1) the identification of novel transcripts that pass the 200 nt 
length threshold and (2) evaluation of their coding potential (Fig. 3.2.2).  Large-scale lncRNA 
discovery efforts are often followed by gene-specific validations.  The newly acquired 
information can then be consolidated into public databases, thus feeding back into the discovery 
process to facilitate identification of greater number of lncRNAs with higher confidence.  In the 
following section, we highlight the major approaches used for lncRNA discovery. 
 
3.2.2.1. Identification of LncRNA Transcripts – “Omics” Approaches 
 A number of different groups and consortia have used high-throughput sequencing 
technology and bioinformatics to facilitate non-coding RNA discovery.   
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Figure 3.2.2  Methods for the identification of lncRNAs.  
 
Schematics showing the strategies and approaches being used for the large-scale discovery and 
annotation of lncRNAs. The methods for the identification of novel transcripts include cDNA 
cloning, detection of mature cDNAs by RNA-seq, detection of TSS and TTS by CAGE, TSS-seq 
and 3P-seq as well as gene-specific RACE experiments, detection of transcription units by 
nascent transcript profiling using GRO-seq and by inference from histone modifications using 
ChIP-seq, and an integration of the abovementioned methods. Experimental and computational 
methods are then used to evaluate the coding potential of the identified novel transcripts to 
determine if they fit the definition of lncRNAs. 
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 cDNA cloning.  RIKEN's FANTOM (Functional Annotation of the Mammalian Genome) 
consortium pioneered the genome-wide discovery of lncRNAs, publishing a set of 34,030 
polyadenylated lncRNAs from mouse in 2005(Carninci, Kasukawa et al. 2005).  In addition, they 
isolated and cloned mouse full-length cDNA libraries for 5’- and 3’sequencing, and developed 
their own bioinformatics methods to map these transcripts to the mouse genome, resulting in 
102,281 cDNAs as the starting point of lncRNA identification.  To evaluate the coding potential 
of these cDNA transcripts, they searched for the presence of (1) protein-domain-like regions 
from Pfam(Finn, Mistry et al. 2006) and SUPERFAMILY databases(Wilson, Madera et al. 2007; 
Wilson, Pethica et al. 2009) and (2) transmembrane regions predicted by the TMHMM 
program(Krogh, Larsson et al. 2001), coiled coil regions predicted by the NCOIL program, and 
signal peptides predicted by the SignalP program(Nielsen, Engelbrecht et al. 1997).  The absence 
of such protein-domain-like regions and the lack of open reading frame (ORF) longer than 100 
amino acids were used to annotate one third of the cDNA transcripts as lncRNAs. 
 Histone modification signatures.  In 2009, Guttman and colleagues proposed a different 
strategy that used global histone modificaton signatures to identify novel lncRNAs(Guttman, 
Amit et al. 2009).  Using this approach, lncRNAs were defined as polyadenylated Pol II 
transcripts whose entire transcription units are longer than 5 kb and are well-separated from 
known protein-coding and microRNAs genes (the “lincRNA” definition note above).  Using 
chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq), the 
authors generated genome-wide histone modificaton maps, focusing on those signatures 
associated with Pol II transcription (i.e., H3K4me3 at the promoter and H3K4me36 along the 
gene body), which served as markers of transcription units genome-wide.  Polyadenylated exons 
were identified by microarray analyses with polyadenylated RNA across a random sample of 350 
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regions out of all 1675 transcription units identified.  Due to a lack of splicing information, a 
conservative length cutoff of 5 kb was used to fulfill the length requirement of >200 nt.  Codon 
substitution frequency (CSF)(Clamp, Fry et al. 2007), a measure of coding potential that 
examines evolutionary signatures characteristic to alignments of conserved coding regions, was 
evaluated for all intergenic transcripts in all three reading frames to confirm that the majority of 
the putative transcripts lack significant coding potential.  Using this approach, the authors were 
able to identify approximately 1600 putative lncRNAs across four mouse cell types and about 
3300 lncRNAs across six human cell types. 
Identification of transcription units.  Another approach that can be used to identify 
novel ncRNAs is the identification of transcription units.  Methods that detect the densities of 
elongating RNA polymerases along the genome, such as GRO-seq(Core, Waterfall et al. 2008; 
Hah, Danko et al. 2011) or native elongating transcript sequencing (NET-seq)(Churchman and 
Weissman 2011), can be used to define the transcription units and serve as the basis for transcript 
discovery. A modified version of GRO-seq that incorporates initial steps of Rapid Amplification 
of 5’-end (5’ RACE)(Frohman, Dush et al. 1988) is useful in determining the exact transcription 
start sites (TSS) of all transcripts.  Additional genome-wide methods that facilitate the 
determination TSS include new cap-analysis gene expression (CAGE) (Shiraki, Kondo et al. 
2003) and TSS-seq(Wakaguri, Yamashita et al. 2008; Tsuchihara, Suzuki et al. 2009).  Gene 
identification signature and gene signature cloning ditag technologies, as shown in 
FANTOM3(Carninci, Kasukawa et al. 2005), can be used for the identification of sequences 
corresponding to both the TSS and the transcription termination sites.  A method known as 
poly(A) position profiling by sequencing (3P-seq) can also be used to more precisely determine 
the directionality and end position of the polyadenylated transcription units(Jan, Friedman et al. 
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2011; Ulitsky, Shkumatava et al. 2011; Nam and Bartel 2012).  Nevertheless, while these 
methods delineate the transcriptional landscape of potential lncRNA genes, information from 
RNA-seq will still be essential in elucidating the structure of the mature RNA transcripts 
contained within the corresponding transcription units, will in turn reveal the exact reading 
frame, allowing subsequent evaluation of coding potential. 
 Mature RNA structure.  Characterization of the exon structure of lncRNAs has been 
facilitated by the development of bioinformatics algorithms that perform ab initio transcriptome 
reconstruction.  Using programs such as Cufflinks(Trapnell, Williams et al. 2010) or 
Scripture(Guttman, Garber et al. 2010), entire transcriptomes of mammalian cells can be 
reconstructed using only RNA-seq reads and the genome sequence.  RNA-seq reads directly 
reflect the position and structure of mature RNA transcripts.  Compared to histone modification 
signature-based transcript determination, RNA-seq analysis gives a more accurate measurement 
of the length of mature RNA transcripts and information about exon-intron structure reveals the 
actual reading frame, allowing for more accurate calculation of coding potential.  In the initial 
report using Scripture for transcript annotation, the authors identified over a thousand novel 
lncRNAs in three mouse cell types(Guttman, Garber et al. 2010). These lncRNAs are 
polyadenylated and multi-exonic, and have an average mature transcript length of 859 nt with 
very low coding potential. 
 More recently, both Cufflinks and Scripture have been used to assemble transcripts from 
RNA-seq datasets of very high sequencing depth in an attempt to accurately identify 
comprehensive lists of lncRNAs.  One study examined lncRNAs in 24 human tissues and cell 
types, and cataloged the results in the Human Body Map lncRNA database(Cabili, Trapnell et al. 
2011).  Another study looked across eight time points during zebrafish embryogeneisis(Pauli, 
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Valen et al. 2012).  The combined use of two independent assembly programs, together with 
high sequencing depth on multiple cells types or across multiple developmental stages, 
strengthens the confidence of the discovery process, especially because lncRNAs, as a group, 
have low expression levels, are highly cell-type specific, and are tightly developmentally 
regulated.  In both studies, low CSF scores and the absence of Pfam domains were absolutely 
required for designation as a lncRNA, introducing extra criteria to ensure the non-coding status 
of identified lncRNAs. 
 Integration of approaches.  Researchers have developed and improvised a variety of 
strategies to identify and annotate lncRNAs genome-wide.  Moreover, they have integrated 
elements from these pipelines to facilitate lncRNA discovery.  For example, in an effort to 
identify lncRNAs genome-wide in zebrafish, Ulitsky and colleagues also used H3K4me3 and 
H3K36me3 to mark promoters and gene bodies, but supplemented the histone modification maps 
with 3P-seq to more precisely map the polyadenylated end positions(Ulitsky, Shkumatava et al. 
2011).  They also incorporated existing transcriptome datasets, such as RNA-seq, annotated 
ESTs, and full-length cDNAs, to partially compensate for the lack of accurate mature RNA 
structures.  A coding potential calculator (CPC)(Kong, Zhang et al. 2007) was used to determine 
the coding potential of each transcript. Collectively, the authors bioinformatically integrated 
multiple genomic datasets and identified 550 distinct lncRNAs in zebrafish. 
 
3.2.2.2. Evaluation of Coding Potential  
By definition, lncRNAs are unable to code for proteins.  Determining the coding potential 
of a lncRNA, however, can be difficult.  Three determinants have commonly been used for 
distinguishing noncoding RNAs from all identified RNAs: the length of longest ORF, 
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bioinformatically calculated coding potential, and the presence of coding potential for conserved 
protein domains.  Among them, calculation of coding potential is the least straightforward.  It 
involves the analysis of DNA alignments and codon usage across multiple species, favoring 
changes in amino acids that will preserve structural similarity versus changes that may lead to 
dramatic alterations in protein structure.  In addition to the CSF and CPC scores mentioned 
above, other computational approaches examining coding potential include 
CSTminer(Castrignano, Canali et al. 2004), QRNA(Rivas and Eddy 2001) and CRITICA(Badger 
and Olsen 1999).  CONC  (Coding Or NonCoding) is a program that was developed based on 
support vector machines and can be used to classify transcripts according to features including 
peptide length, amino acid composition, predicted secondary structure content, predicted 
percentage of exposed residues, compositional entropy, number of homologs from database 
searches, and alignment entropy(Liu, Gough et al. 2006).  The identification and characterization 
of a growing set of lncRNAs has allowed experimental validation of these bioinformatic 
approaches.  
 While most studies of lncRNAs have used the aforementioned bioinformatic approaches 
to evaluate their coding potential, ribosomal profiling is a direct experimental approach that can 
be used to address this issue.  It was first developed to investigate the process of translation with 
sub-codon resolution, involves deep sequencing of ribosome-protected RNA fragments(Ingolia, 
Ghaemmaghami et al. 2009).  It was then adapted to distinguish polyribosome-associated RNAs 
that are likely being translated from others that are more likely to be noncoding.  Nam and Bartel 
identified polyadenylated transcripts in C. elegans using both RNA-seq and 3P-seq(Nam and 
Bartel 2012).  Over 300 lncRNAs were identified from these transcripts after filtering through 
the coding potential threshold calculated from the CPC program and removing those that can be 
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detected in ribosome profiling experiments.  However, ribosomal profiling requires further 
testing and validation, since association with the ribosome alone cannot be taken as the absolute 
evidence of protein coding potential.  For example, both H19 and TUG1, two well-characterized 
lncRNAs, can be detected in association with the ribosome(Li, Franklin et al. 1998; Ingolia, 
Lareau et al. 2011).  Some researchers have argued that instead of simply eliminating all 
transcripts identified in association with ribosomes (i.e., from ribosome profiling experiments), a 
more carefully examination of the preferential usage of a specific coding frames and features 
conferred by the release of the ribosomal complex at the site of the stop codon should be used to 
determine whether the transcript is productively translated. 
 
3.2.2.3. Gene-Specific Validations 
High-throughput sequencing and bioinformatics methods have led to tremendous 
progress in the large-scale identification of lncRNAs.  Nevertheless, empirical validation of 
lncRNAs using a set of classical molecular biology techniques is still required.  After learning 
the approximate location of a potential lncRNA transcript using global approaches, 5’- and 3’-
RACE experiments can be carried out to determine the exact transcription initiation and 
termination sites, and to examine the presence or the absence of 5’ cap and 3’ poly(A) tail.  PCR-
based approaches can be used to isolate full-length cDNAs for those lncRNAs whose cDNAs are 
not available from public repositories, followed by traditional Sanger sequencing to obtain 
precise information on the exact exon-intron structure of the mature lncRNA transcript.  
Validation of the noncoding status of a putative lncRNA is less straightforward.  In vitro 
transcription-translation assays have been used, but may give inconclusive results.  In the case of 
SRA, functional outcomes associated with the RNA transcript were monitored after the 
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introduction of different missense and frameshift mutations, illustrating how one can prove that a 
lncRNA functions in a coding-independent manner(Lanz, McKenna et al. 1999).  Nevertheless, 
this approaches demands prior knowledge of the functions of the identified lncRNAs. 
 
3.2.2.4. Cataloging LncRNAs in Public Databases 
 The identification and characterization of a growing set of lncRNAs has provided 
additional insights into the properties of lncRNAs as a group, which facilitate subsequent efforts 
in lncRNA research.  To make better use of the power of recursion, a number of lncRNA 
databases have been developed to consolidate and summarize the growing body of information.  
 Early lncRNA databases.  In 2003, Barciszewski’s group developed one of the first 
databases, NcRNAdb, which focuses on functional noncoding RNA transcripts that perform 
regulatory roles in the cell(Szymanski, Erdmann et al. 2003).  In addition to small noncoding 
RNAs, this database consolidated the limited number of lncRNAs that had been identified at that 
time, but later gathered sequences from other relatively earlier databases including FANTOM3 
(described above), GenBank, and H-Invitational Databases (H-InvDB). It was last updated in 
2006, and has over 30,000 individual sequences from 99 species of Bacteria, Archaea and 
Eukaryota(Szymanski, Erdmann et al. 2007). 
 Second generation lncRNA databases.  fRNAdb (2009)(Mituyama, Yamada et al. 2009) 
and NONCODE (2011)(Bu, Yu et al. 2012) are more recent databases that compile and integrate 
existing information of ncRNAs, including lncRNAs.  They also provide support for associated 
computational analysis. fRNAbd currently contains 509,795 sequences and NONCODE has 
423,976.  A total of 1635 lncRNAs in NONCODE have been annotated with potential functions.    
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A number of public repositories for lncRNAs, such as Noncoding RNA Expression 
Database (NRED, 2009)(Dinger, Pang et al. 2009) and lncRNAdb (2011)(Amaral, Clark et al. 
2011), have also been developed.  NRED is linked to lncRNAdb. Both repositories integrate 
gene expression information with evolutionary conservation, secondary structure, genomic 
context, and antisense relationships for the cataloged lncRNAs.  In the case of lncRNAdb, 
features such as subcellular localization and functional evidence associated with these lncRNAs 
have also been included. 
Other catalogs collect lncRNAs using in-house annotation pipelines, such the Human 
Body Map lincRNA database (described above)(Cabili, Trapnell et al. 2011) and 
GENCODE(Derrien, Johnson et al. 2012), which are the most current and comprehensive. 
GENCODE, which is part of the ENCODE project, attempts to annotate all evidence-based gene 
features (cDNA, EST sequences) in the entire human genome at a high accuracy, and generates 
annotations of both protein-coding and noncoding genes, including a large number of lncRNAs.  
The latest version of GENCODE (February 2013 freeze, GRCh37) contains 13333 lncRNA 
genes from 22631 lncRNA loci transcripts. 
 Looking forward.  At this point, a substantial proportion of all polyadenylated lncRNAs 
expressed in human have already been annotated, but these annotations need additional 
refinement and validation.  In addition, give the tissue- and species-specificity of lncRNAs, there 
are most certainly more to be discovered.  The majority of identified lncRNAs remains 
uncharacterized, but holds great promises for novel biological discoveries.  With the existing 
annotations and functional databases, molecular biologists interested in the functional 
characterization of lncRNAs are no longer tied to the requirement of bioinformatics expertise 
and high cost of deep sequencing associated with de novo identification of lncRNAs.  In many 
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cases, information extracted from existing databases may be a good starting point for 
characterizing previously identified lncRNAs with unknown functions and gain additional 
insights into the general features of lncRNAs as a group. 
 
3.2.3. Functional Characterization of LncRNAs 
Assigning molecular, cellular, and physiological functions to well annotated lncRNAs is 
the next great challenge in the field.  Classical biochemical and molecular biology techniques 
have been instrumental in gene-specific functional characterization of lncRNAs.  Gain-of-
function and loss-of-function experiments can be used to validate the role of lncRNAs in 
modulating specific cellular processes.  But, it is often challenging to determine whether an 
uncharacterized lncRNA plays an important functional role or which cellular process can be 
probed to yield an observable phenotype.  Indeed, more efficient functional analyses, including 
high-throughput approaches linking lncRNAs to their probable functions, are required to keep 
pace with the tremendous progress made in lncRNA discovery.  Below, we review a number of 
genomic strategies that facilitate large-scale functional characterization of lncRNAs. 
 
3.2.3.1. Expression Profiling across Spatial and Temporal Gradients 
The expression of lncRNAs is often cell type-, tissue-, and context-dependent.  Therefore, 
the involvement of lncRNAs in specific cellular processes may be inferred by their differential 
expression patterns across tissues and across different developmental- or signal-regulated time 
points.  For instance, Klattenhoff et al. identified lncRNAs that play critical roles in 
cardiovascular lineage commitment by reasoning that such candidates should demonstrate 
expression patterns restricted to specific cell types during embryonic stem cell (ESC) 
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differentiation (Klattenhoff, Scheuermann et al. 2013).  They measured lncRNA expression in 
mouse ESCs and in differentiated tissues using RNA-seq and focused on 47 candidates whose 
expression levels were elevated in ESCs compared to other differentiated tissues.  Among them, 
Braveheart, a lncRNA with higher expression in the heart relative to other tissues, was selected 
and characterized as a mediator of epigenetic regulation of cardiac commitment.  Similarly, 
Kretz at el. focused on lncRNAs in keratinocyte differentiation, performing RNA-seq in primary 
keratinocytes during a calcium-induced differentiation time course (Kretz, Siprashvili et al. 
2013).  TINCR was one of the candidates chosen for further characterization, as it is among the 
most highly induced annotated lncRNAs whose expression changes during differentiation.  
Consistently, TINCR was found to be a key lncRNA required for somatic tissue differentiation 
by binding to differentiation mRNAs to stabilize their expression.  These are just two examples 
where transcriptome profiling experiments across either spatial or temporal gradients generate 
clues to the functions of annotated lncRNAs.  Since most lncRNA discovery approaches 
incorporate transcriptome profiling, it can be easily envisaged that when carefully designed, such 
efforts will not only yield information on the annotation and expression of novel and existing 
lncRNAs genes, but also shed light on the probable functions of a selected group of newly 
annotated lncRNAs. 
 
3.2.3.2. Coding-Noncoding Coexpression Relationships – “Guilt-by-Association”  
While the spatial and temporal gradients are helpful in choosing and characterizing a 
selected group of lncRNAs, additional approaches are needed for other situations.  Guttman and 
colleagues have proposed a genomic approach to allow global functional characterization of 
lncRNAs, also known “guilt-by-association”, which relies on correlation and clustering analysis 
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performed on mRNA expression profiling data and gene ontology or functional pathway 
analyses (Fig. 3.2.3) (Guttman, Amit et al. 2009).  In this approach, groups of lncRNAs of 
unknown function are associated with groups of protein-coding mRNAs known to be involved in 
a specific cellular process based on a common expression pattern across cell-types and tissues.  
A positive correlation between the expression profile of a lncRNA and mRNAs suggests 
common function in the same cellular process.  In their original paper, lincRNA-p21 was 
predicted to associate with p53-mediated DNA damage responses, with lincRNA-p21 later 
validated as a p53 target that modulates apoptotic responses upon DNA damage (Huarte, 
Guttman et al. 2010).  The guilt-by-association approach is a useful first pass in assigning 
putative biological functions to lncRNAs and provides a working hypothesis for targeted 
perturbation experiments.  
Zhao’s group has expanded the analysis of gene coexpression relationships into a coding-
noncoding coexpression network (CNC), making computational prediction of lncRNA functions 
through the evaluation of network characteristics (Liao, Liu et al. 2011).  In addition to the 
coexpression network, co-localization relationships were also taken into consideration in their 
analysis.  They focused on mouse lncRNAs annotated by FANTOM3 and extracted gene 
expression information from re-annotated Affymetrix Mouse Genome Array data.  Ultimately, 
they predicted functions for 349 lncRNAs and further streamlined the application into a practical 
user interface called the Non-coding RNA Function Annotation Server (ncFANs) (Liao, Xiao et 
al. 2011).  ncFANs is a useful tool for global prediction of lncRNA function, forming the basis of 
functional annotation in the NONCODE database, but its application is limited to annotated 
lncRNAs associated with corresponding microarray-based gene expression data.  
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Figure 3.2.3  “Guilt-by-association” approach.  
 
Schematics showing the “guilt-by-association” approach that relies on correlation and clustering 
analysis to serve as a first-pass method in determining the possible functions of uncharacterized 
lncRNAs. A correlation matrix is generated based on the correlation of expression between every 
pair of lncRNAs and mRNAs across many tissue samples and cell types. For each lncRNA, the 
corresponding list of mRNAs are ranked based on their correlation coefficients and it goes 
through the gene set enrichment analysis to produce statistically enriched functional pathways 
that are associated with the lncRNA. The procedure is performed for all lncRNAs of interest, and 
a “guilt-by-association” matrix can be generated through hieratical clustering of the enrichment 
relationships, resulting in groups of lncRNAs associated with distinct functional roles. 
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3.2.3.3. A Role for LncRNAs in Cis-Regulation of Gene Expression 
One rationale behind the use of co-localization relationships in CNC-based functional 
characterization is that many lncRNAs have been shown to play a cis-regulatory role in the 
expression of nearby genes (Fig. 3.2.4A).  For example, the gene for the ANRIL lncRNA 
overlaps and runs antisense to the gene encoding p15, mediating its gene silencing (Kotake, 
Nakagawa et al. 2011). In contrast, a chromatin-associated lncRNA CAR intergenic 10 is 
coexpressed with its flanking coding genes, FANK1 and Adam12, and helps to maintain their 
expression by establishing active chromatin structures (Mondal, Rasmussen et al. 2010).   
The cis-regulatory function of HOTTIP involves an additional element.  It is a lncRNA 
transcribed from the 5’ end of the HoxA cluster and functions to activate the expression of 
neighbouring genes (Wang, Yang et al. 2011).  Nevertheless, its influence extends to multiple 
distal HoxA genes owing to chromosome looping.  The authors used chromosome conformation 
capture carbon copy (5C), a high throughput method to identify physical chromatin interaction, 
suggesting a model of how a cis-acting lncRNA can affect distal genes. 
In a separate study, Ørom and colleagues selected candidates from the GENCODE 
database and suggested an enhancer-like function for several lncRNAs, which they termed 
ncRNA-activating (ncRNA-a), in activating the expression of neighbouring coding genes using 
heterologous transcription assays (Orom, Derrien et al. 2010). Similar to HOTTIP, some of the 
ncRNA-a were connected to their target genes through long-range chromatin loops. Lai and 
colleagues further demonstrated that these lncRNAs recruit the Mediator complex to their targets 
genes, and the Mediator complex plays an important role in forming DNA loops between the 
lncRNAs and their targets, and in mediating ncRNA-a-dependent gene activation (Lai, Orom et 
al. 2013).  
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The co-localization relationship has been exploited even further.  To study lncRNAs 
involved in cell cycle regulation, Hung and colleagues looked in the proximity of known cell 
cycle genes and designed their approaches based on both “guilt-by-association” strategy and the 
cis-regulatory model (Hung, Wang et al. 2011).  They used an ultra high-density array that tiles 
the promoters of 56 cell-cycle genes to interrogate 108 samples representing diverse conditions 
and perturbations, identifying 216 putative lncRNA transcripts originating proximal to these cell 
cycle gene promoters.  Subsequently, they examined the coding-noncoding coexpression map 
across the conditions and clustered lncRNAs into different cell cycle-associated functions.  The 
lncRNA PANDA (P21 associated ncRNA DNA damage activated) was selected for further 
analysis and was shown regulate apoptosis, consistent with the prediction. 
 
3.2.3.4. A Role for LncRNAs in Trans-Regulation of Gene Expression 
When coexpression and co-localization relationships are used as basis for functional 
prediction, direct perturbation experiments are required to validate the prediction.  Therefore, 
Guttman and colleagues suggested a more direct approach for the functional characterization of 
lncRNAs, performing RNAi-based loss-of-function experiments and monitoring consequent 
changes in global gene expression (Guttman, Donaghey et al. 2011).  They focused on 
previously identified lncRNAs expressed in embryonic stem cells and were able to successfully 
knock down the expression of 147 lncRNAs using custom designed short hairpin RNAs.  For 
137 lncRNAs, knockdown resulted in significant global changes in gene expression as shown in 
microarray analysis, and the majority had little effect on neighbouring genes, suggesting that 
these lncRNAs most likely affect gene expression in trans (Fig. 3.2.4B).  
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Figure 3.2.4  Cis and trans gene regulation by lncRNAs. 
(A and B) LncRNAs can mediate transcription regulation and epigenetic control through 
chromatin-modifying proteins and other transcriptional coregulators in cis or trans.  (A) In cis 
regulation, the lncRNA acts on target genes that are either located near the lncRNA gene or can 
be looped to the proximity of the lncRNA gene through higher-order chromatin structures. (B) In 
trans regulation, the lncRNA acts on target genes located distally to the lncRNA gene, possibly 
on another chromosome. Blue and red arrows indicate lncRNA and mRNA genes, respectively. 
Bent arrows indicate the TSSs of the genes. 
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These were not the first lncRNAs that have been associated with trans-regulation.  
HOTAIR, a well characterized lncRNA involved in developmental processes, is co-expressed 
with the HoxC genes, interacts with the chromatin-modifying PRC2 complex, and functions in 
trans to repress HoxD expression (Rinn, Kertesz et al. 2007).  Interactions between HOTAIR and 
PRC2 proteins have been verified in both RNA-pulldown (captures proteins associated with a 
RNA bait) and RNA immunoprecipitation (RIP) (captures RNAs that are associated with 
proteins of interest using specific antibodies).  
Indeed, there are many other lncRNAs that have been shown to interact with PRC2, 
including Braveheart (described earlier) (Klattenhoff, Scheuermann et al. 2013) and XIST (Zhao, 
Ohsumi et al. 2010), which coats the X chromosome to initiate and propagate X-inactivation 
(Penny, Kay et al. 1996; Marahrens, Panning et al. 1997).  Other lncRNAs have been shown to 
interact with additional chromatin-modifying complexes.  For example, HOTTIP binds and 
targets the WDR5/MLL complex across the HoxA to maintain active chromatin and coordinate 
homeotic gene expression (Wang, Yang et al. 2011).  In addition, the tissue-specific lncRNA 
Fendrr has been shown to bind both the PRC2 and TrxG/MLL complexes, modulating chromatin 
signatures and gene activities to ensure the proper development of heart and body wall in mouse 
(Grote, Wittler et al. 2013). 
Taken together, the connection between lncRNAs and chromatin-modifying complexes 
forms an appealing model of trans-regulation (Fig. 3.2.5A).  Therefore, Lander and Rinn groups 
coupled the RIP assay to a microarray analysis (RIP-chip) to query many lncRNAs 
simultaneously (Khalil, Guttman et al. 2009).  Among the 3300 human lncRNAs being queried, 
PRC2 or CoREST complexes were found to associate with 38% of them, suggesting that 
lncRNAs interacting with chromatin-associated complexes could be a common mechanism.  In  
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Figure 3.2.5  A broader view of lncRNA functions. 
(A-F) LncRNAs mediate their functional roles through the regulation of gene expression, via a 
variety of molecular mechanisms both in the nucleus and in the cytoplasm. The nuclear functions 
of lncRNAs include (A) interaction with chromatin modifying complexes to alter epigenetic 
modifications, (B) interaction with transcription factors (TFs) such as nuclear receptors (NRs), 
and additional transcriptional coregulators to act as transcriptional cofactors themselves, and (C) 
having a decoy sequence to titrate away and repress the activity of DNA-binding TFs. Their 
cytoplasmic functions include (D) acting as a microRNA sponge as in the case of ceRNAs, (E) 
interaction with STAU1 and the regulation of STAU1-dependdent mRNA stability, and (F) 
interaction with the cytoplasmic RNA-binding protein Rck/p54 to inhibit translation.  
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addition, while RIP-chip requires prior knowledge of lncRNA sequences, Zhao and colleagues 
improved the method by replacing the microarray analysis with high throughput sequencing, 
which allows for unbiased identification of lncRNAs that interacts with candidate proteins 
(Zhao, Ohsumi et al. 2010).  In this case, they tested their method on PRC2 and identified a 
genome-wide pool of >9000 PRC2-interacting RNAs in mouse embryonic stem cells. Not   
surprisingly, XIST is highly enriched in PRC2 RIPseq experiments, serving as a good positive 
control.  
RIP-based experiments have helped to establish direct interactions between lncRNAs and 
proteins, suggesting that lncRNAs can act as molecular scaffolds to guide chromatin modifying 
complexes to their target genomic locations.  Coupled with profiles of changes in chromatin 
signatures by ChIP-seq, the target sites of lncRNA action can be deduced.  For example, changes 
in H3K4me3 and H3K27me3 marks were observed in HOTAIR knockdown foreskin fibroblasts, 
consistent with the modes of action of HOTAIR in targeting LSD1 and PRC2 to specific 
genomic locations to affect histone modifications (Rinn, Kertesz et al. 2007).  Nevertheless, 
direct methods that capture the interaction between lncRNAs and chromatin sites have been 
developed recently: (1) chromatin isolation by RNA purification (ChIRP) (Chu, Qu et al. 2011) 
and (2) capture hybridization analysis of RNA targets (CHART) (Simon, Wang et al. 2011). In 
both methods, chromatin is crosslinked to lncRNA:protein adducts in vivo, followed by affinity 
capture of target lncRNA:chromain complexes using tiling antisense oligonucleotides in ChIRP 
or pre-selected oligonucleotides targeting RNase-H sensitive regions of the lncRNA in CHART. 
LncRNA-bound DNA were then isolated and sequenced to generate a genomic map of lncRNA 
binding sites. Such methods have been applied to trans-acting lncRNAs such as the Drosophila 
lncRNA roX2 and human HOTAIR to confirm their genomic binding sites. 
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3.2.3.5. Beyond the Nucleus: A Broader View of LncRNA Functions 
LncRNAs play important roles in both cis- and tran-regulation of transcription, but 
continued studies are needed to determine the relative contributions of cis and trans mechanisms 
of lncRNA function.  There is a strong bias in the field for this potential aspect of lncRNA 
function, leading to the common belief that lncRNAs as a group are mostly involved in 
transcriptional regulation.  Although lncRNAs as a group may show a slight enrichment for the 
nuclear compartment, many lncRNAs are predominantly or even exclusively cytoplasmicly 
localized.  Inherent biases in some previous analytical approaches, however, have propagated the 
emphasis on nuclear functions for lncRNAs.  For example, PRC2 RIP-based methods have 
suggested that a large number of lncRNAs are involved in PRC2-mediated transcriptional 
repression.  Nevertheless, the RIP protocol used limited the analysis to nucleus-retained RNAs, 
leaving open the possibility that a larger proportion of lncRNAs interact with cytoplasmic 
proteins. Indeed, there have been an increasing number of examples of cytoplasmic lncRNAs.  
Among them, half-STAU1-binding site RNAs have been shown to transactivate the binding of 
STAU1 protein to its target mRNAs to facilitate mRNA decay (Fig. 3.2.5E) (Gong and Maquat 
2011).  On the other hand, TINCR, another lncRNA that has been shown to bind STAU1, 
interacts with differentiation mRNAs to mediate their stabilization in a STAU1-dependent 
manner (Fig. 3.2.5E) (Kretz, Siprashvili et al. 2013). 
Furthermore, when Huarte et al. attempted to delineate the mechanism of action of 
lincRNA-p21 by identifying its interaction partners using RNA pull down, nuclear extract was 
used, and the nuclear RNA binding protein hnRNP was found to associate with this lncRNA to 
facilitate its action in mediating gene repression (Huarte, Guttman et al. 2010).  Yoon and 
colleagues confirmed this interaction in an anti-hnRNP RIP experiment (Yoon, Abdelmohsen et 
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al. 2012).  More interestingly, as they searched for RNA partners for the cytoplasmic RNA 
binding protein HuR in anti-HuR RIP experiment using whole cell lysates, lincRNA-p21 was 
readily enriched as well (Yoon, Abdelmohsen et al. 2012).  This interaction accelerates the 
degradation of lincRNA-p21, which in turn ameliorates its interaction with additional 
cytoplasmic RNA-binding proteins Rck/p54, and derepresses the expression of a subset of target 
mRNAs, elucidating an additional role of cytoplasmic lincRNA-p21 as a post-transcriptional 
inhibitor of translation (Fig. 3.2.5F). 
LincRNA-p21 is just one example showing that methods limited to the characterization 
of nucleus-retained lncRNAs are thus not sufficient to provide us with a complete spectrum of 
functional roles played by lncRNAs. Delineating the cellular localization of lncRNAs in an 
unbiased manner should be one of the first steps in used for gathering more clues on their 
possible functional roles.  Nucleus-retained lncRNAs are more likely to be involved in 
transcriptional regulation, while cytoplasmic lncRNAs may have other functions.  RNA 
fluorescence in situ hybridization (FISH) is a popular method that has been used to visualize the 
cellular localization of lncRNAs, but challenges remain for a high-throughput FISH approach 
that examines many lncRNAs simultaneously.  Alternatively, lncRNAs can be extracted from 
each of the physically defined cellular compartments and then sequenced, revealing the relative 
amount of each lncRNA in the various cellular fractions.  With modifications as described in 
Yoon et al., RIP-based methods can also be used with key cytoplasmic proteins that act in 
important cellular pathways to identify and characterize cytoplasmic lncRNAs involved in those 
pathways (Yoon, Abdelmohsen et al. 2012).  Furthermore, Kretz et al, who characterized 
TINCR, utilized a protein microarray analysis containing approximately 9400 recombinant 
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human proteins (Human Protoarray) to identify the TINCR-STAU1 interaction in the cytoplasm 
(Kretz, Siprashvili et al. 2013). 
 
3.2.3.6. Lessons Learned from the Best-Characterized LncRNAs 
Using methods described above and additional strategies, a growing number of lncRNAs 
have been characterized molecularly and functionally.  A limited few are as well characterized as 
some protein-coding RNAs.  Below, we summarize the current status of the few best-
characterized lncRNAs to date and highlight the lessons learned from these examples. 
XIST.  The X-inactive-specific transcript (XIST) was one of the first lncRNAs to be 
discovered in mammals(Borsani, Tonlorenzi et al. 1991; Brockdorff, Ashworth et al. 1991; 
Brockdorff, Ashworth et al. 1992; Brown, Hendrich et al. 1992).  It is responsible for the 
initiation and spreading of X-chromosome inactivation (XCI) in female somatic cells(Penny, 
Kay et al. 1996; Marahrens, Panning et al. 1997; Wutz and Jaenisch 2000; Wutz, Rasmussen et 
al. 2002).  XIST is transcribed from the XCI loci and acts in concert with the transcription factor 
YY1 and several other lncRNAs from the same locus (e.g., RepA, Tsix, Jpx/Enox) to facilitate 
the loading of PRC2 and initiate DNA methylation and the subsequent chromosome-wide 
silencing(Lee, Davidow et al. 1999; Lee and Lu 1999; Sado, Hoki et al. 2005; Ogawa, Sun et al. 
2008; Zhao, Sun et al. 2008; Tian, Sun et al. 2010; Jeon and Lee 2011). It is one of the best 
examples of multiple lncRNAs utilizing their base complementarity properties to collaborate 
with each other and with proteins to achieve a common cellular function.  This could be a 
recurring theme with lncRNAs, which may base pair with DNA in the genome or RNA elements 
in the transcriptome, creating unique interfaces for RNA-protein interactions. LncRNAs 
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encompass RNA motifs with variable lengths, offering advantages over small protein motifs and 
allowing more specificity in targeting to unique addresses. 
Even after more than two decades of extensive research, the exact mechanism of XIST-
mediated spreading of XCI is yet to be fully elucidated.  This is due, in part, to the lack of high 
throughput approaches of sufficient resolution to distinguish allelic differences of the X 
chromosomes.  To address this, Pinter et al. developed allele-specific ChIP-seq, mapping the 
positions of the PRC2 component EZH2 and XCI-associated histone marks on the inactive (Xi) 
and active (Xa) X chromosomes separately over a developmental time course(Pinter, Sadreyev et 
al. 2012).  The authors presented a model in which XCI is governed by a hierarchy of defined 
PRC2 stations that spread H3K27 methylation in cis.  Following in the path of allele-specific 
ChIP-seq, allele-specific ChIRP or CHART of XIST on the X chromosomes could be used to 
visualize the spreading of XIST on the inactive X chromosome along the developmental axis 
more directly. 
MALAT1.  MALAT1 is one of the first cancer-associated lncRNAs discovered, hence its 
name metastasis-associated lung adenocarcinoma transcript 1(Ji, Diederichs et al. 2003).  It is 
extremely abundant and highly conserved over its full length across all mammalian species, both 
properties that highlight its likely importance(Ji, Diederichs et al. 2003; Hutchinson, Ensminger 
et al. 2007; Bernard, Prasanth et al. 2010).  MALAT1 localizes to nuclear bodies known as 
nuclear speckles(Yang, Lin et al. 2011), suggesting functions in the nucleus.  In cell-based 
models, MALAT1 has been shown to regulate alternative splicing and gene expression at the 
molecular level(Bernard, Prasanth et al. 2010; Tripathi, Ellis et al. 2010; Yang, Lin et al. 2011), 
contributing to its association with metastatic lung adenocarcinoma.  Given these preliminary 
results, the observation that MALAT1 knockout mice display little observable phenotype, 
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especially with respect to splicing or gene expression, is surprising(Zhang, Arun et al. 2012).  
The field must address why lncRNAs that show cell-based phenotypes are not functional in vivo, 
as is the case with MALAT1.  Parallels between lncRNAs and the better understood class of 
microRNAs may help to explain such conundrums.  Phenotypic evaluation of microRNA 
knockout mice has revealed similar disappointing phenotypes(Liu, Bezprozvannaya et al. 2008; 
Jin, Hirokawa et al. 2009; Williams, Valdez et al. 2009; Park, Jeker et al. 2012).  But new studies 
suggest that the most dramatic phenotypes often arise in response to specific cellular signals, 
such as special diet or stress, or under a compromised genetic background(van Rooij, Sutherland 
et al. 2007; Callis, Pandya et al. 2009).  In other words, the appropriate cellular context is 
essential. 
In this regard, given the association between MALAT1 and lung adenocarcinoma, it will 
be interesting to cross the MALAT1 knockout mice with genetic models of lung cancer, or to 
generate lung-specific MALAT1 knockouts and treat them with oncogenic agents, to determine 
whether any transcriptional and phenotypic consequences arise.  In this regard, Gutschner et al. 
diminished MALAT1 expression in A549 human lung adenocarcinoma cells using a zinc finger 
nuclease-mediated KO approach(Gutschner, Hammerle et al. 2013). They observed changes in 
gene expression and impairment in the metastatic potential of these MALAT1-deficient cells in 
mice xenograph experiments, once again established a critical role of MALAT1 as a regulator of 
gene expression governing hallmarks of lung cancer metastasis(Gutschner, Hammerle et al. 
2013). Not unlike the situation with microRNAs, when probing the in vivo functions of 
lncRNAs, it is important to find the right context in order to uncover the observable phenotype. 
HOTAIR.  HOTAIR is a 2.2 kb lncRNA transcribed from the HOXC locus that functions 
to repress transcription in trans across 40 kilobases of the HOXD locus(Rinn, Kertesz et al. 
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2007).  Similar to MALAT1, HOTAIR is a cancer-associated lncRNA, including breast, 
colorectal, nasopharyngeal, and hepatocellular cancers(Gupta, Shah et al. 2010; Geng, Xie et al. 
2011; Kogo, Shimamura et al. 2011; Nie, Liu et al. 2013), although its prognostic value in 
clinical oncology is still undetermined.  Mechanistically, it is the first lncRNA to be found to 
associate with PRC2 complexes(Rinn, Kertesz et al. 2007), initiating the subsequent 
characterization of a large number of PRC2-interacting RNAs later known as the PRC2 
transcriptome(Khalil, Guttman et al. 2009; Zhao, Ohsumi et al. 2010).  It is also the first 
mammalian lncRNA to be screened by ChIRP, demonstrating its direct association with GA-rich 
regions of chromatin that nucleate broad domains of Polycomb and H3K27me3 occupancy(Chu, 
Qu et al. 2011).  Tsai and colleagues showed that not only does the 5’ domain of HOTAIR binds 
to PRC2, but the 3’ domain binds LSD1, a chromatin modifying complex that promotes 
H3K4me3 demethylation, suggesting a role for HOTAIR as a molecular scaffold possessing 
distinct RNA domains for protein interactions (Tsai, Manor et al. 2010). 
The characterization of HOTAIR illustrates two aspects of lncRNA function. First, it 
provides a model for the function of a lncRNA that regulates transcription in trans, through 
tethering to chromatin regions and recruiting chromatin modifying complexes.  Second, it shows 
that lncRNAs can be modular, not unlike proteins.  Its functions can be separated into 
independent molecular domains that act in collaboration. These results suggest ways of studying 
lncRNAs in a manner similar to studying proteins. We can draw hints and insights from the 
prediction or biochemical mapping of RNA structures, as well as from information of 
evolutionary conversation, and perhaps can even work towards building a database of lncRNA 
domains or motifs, which will help to elucidate the functions of lncRNAs, much in the same way 
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PFAM(Finn, Mistry et al. 2006) and PROSITE(Hulo, Bairoch et al. 2006) have done for 
proteins.  
 
3.2.4. Emerging Roles of lncRNAs in Molecular Endocrinology 
 As described in the previous sections, efforts to understand the biology of lncRNAs are 
beginning to shed new light on their roles in physiological and pathological processes.  
Accumulating evidence has pointed to key roles of lncRNAs in development and differentiation 
(e.g., XIST, HOTAIR, TINCR, Braveheart, Fendrr), as well as cell proliferation and cell death 
(e.g., PANDA, lincRNA-p21, ANRIL), but lncRNAs are likely to be functionally involved in 
many more, if not all, cellular processes. Emerging evidence has suggested roles for a number of 
lncRNAs in various endocrine functions of the reproductive and metabolic tissues. Most of them 
are involved in hormonal-regulated signaling pathways. 
 Steroid receptor activator (SRA).  The first link between a lncRNA and hormone 
receptor-associated pathways was established more than two decades ago with the discovery of  
steroid receptor activator (SRA) by O’Malley and colleagues(Lanz, McKenna et al. 1999).  SRA 
was initially described as an RNA transcript specifically expressed in steroid hormone target 
tissues, which functions as a steroid receptor coactivator.  The SRA RNA interacts with steroid 
receptor coactivators 1 and 2 (SRC-1, SRC-2) and facilitates ligand-dependent transactivation in 
reporter gene assays.  In a careful series of biochemical and cellular experiments, the authors 
used mutations that introduce early stop codons in SRA and inhibitors of protein synthesis to 
convincingly demonstrate that the coactivator function of SRA is independent of of translated 
protein products.  Subsequent studies have substantiated the earlier findings and identified 
additional interaction partners involving both coactivators (e.g., p68, p72, Pus1p and 
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Pus3p)(Watanabe, Yanagisawa et al. 2001; Zhao, Patton et al. 2007) and corepressors (e.g., 
SHARP and SLIRP)(Shi, Downes et al. 2001; Hatchell, Colley et al. 2006), thus expanding the 
role of SRA as a transcriptional coregulator (Fig. 3.2.5B).  More recently, protein-coding 
isoforms of the SRA gene, containing an extended exon-1, have also been identified(Hube, 
Velasco et al. 2011), making it an interesting case of an RNA with dual roles as both a lncRNA 
and a protein-coding RNA.  Nevertheless, the noncoding isoform displays differential expression 
patterns across different breast cancer cell lines and appears to play oncogenic roles in breast 
cancer tumorigenesis (Chooniedass-Kothari, Hamedani et al. 2006; Leygue 2007; Cooper, Guo 
et al. 2009), making the studies of such lncRNAs highly relevant to endocrine cancer research. 
 Growth arrest-specific 5 (GAS5).  Growth arrest-specific 5 (GAS5) is another lncRNA 
that has been shown to regulate the activity and function of multiple receptors, including the 
glucocorticoid, androgen, mineralcorticoid, and progesterone receptors (Kino, Hurt et al. 2010).  
Unlike SRA, which participates in steroid coactivator complexes as a scaffold, GAS5 forms an 
RNA stem-loop structure to mimic a DNA response element.  In the context of glucocorticoid 
receptor (GR), it interacts with the GR DNA-binding domain and acts as a decoy GR response 
element, titrating GR away from its sites of transcriptional activity in a ligand-dependent manner 
(Fig. 3.2.5C).  The GAS5 RNA accumulates in fasting and growth arrested cells, thus 
functioning as a starvation- or growth arrest–linked riborepressor for GR and possibly other 
nuclear receptors that share the same DNA response element sequence, facilitating steroid-
modulated cell survival and metabolism(Kino, Hurt et al. 2010; Williams, Mourtada-Maarabouni 
et al. 2011). In human adeherent cell lines including 293T and MCF-10A, Mourtada-Maarabouni 
and colleagues have shown that overexpresssion of GAS5 suppresses cell growth and promotes 
apoptosis, and it is found at reduced levels in human breast carcinoma samples compared to their 
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matched controls, suggesting a role of GAS5 as a tumour suppressor(Mourtada-Maarabouni, 
Pickard et al. 2009). 
 Progesterone receptor gene antisense transcripts.  Some receptor-related lncRNAs may 
be more receptor-specific.  Corey’s lab has examined the transcriptional landscape of the 
progesterone receptor (PR) gene and showed the existence of antisense RNA transcripts 
overlapping the PR gene promoter(Schwartz, Younger et al. 2008).  They are likely to be 
lncRNAs, and at least one of them is spliced and polyadenylated.  Although the coding potential 
of these transcripts have not been explicitly evaluated, they appear to be acting at the RNA level 
through base complementarities to other RNA molecules.  Specifically, duplex RNAs, or 
antigene RNAs (agRNAs), complementary to the PR gene promoter increase expression of PR 
mRNA and protein levels after transfection into human breast cancer cells(Janowski, Younger et 
al. 2007; Schwartz, Younger et al. 2008).  Interestingly, the antisense lncRNAs are required for 
the agRNA-mediated activation of the PR gene, possibly through base pairing with the 
agRNAs(Schwartz, Younger et al. 2008; Janowski and Corey 2010).  The possibility that these 
PR antisense lncRNAs are involved in the modulation of PR gene expression is an attractive one, 
and Corey and colleagues continue to search for endogenous agRNA-like molecules that might 
mediate these effects.  microRNAs are possible candidates.  Indeed, the inhibitory effects of 
mir123b on PR gene expression can be inhibited by PR antisense lncRNAs(Janowski and Corey 
2010), suggesting a role of lncRNAs in acting as competing endogenous RNAs (ceRNAs) to 
sequester microRNAs, thus adding to the growing list of lncRNAs acting as ceRNAs in multiple 
cellular models (Fig. 3.2.5D)(Cesana, Cacchiarelli et al. 2011; Karreth, Tay et al. 2011; Salmena, 
Poliseno et al. 2011; Tay, Kats et al. 2011). 
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 Pregnancy-induced noncoding RNA (PINC): A hormone-regulated lncRNA.  The 
examples noted above illustrate how direct or indirect interactions between lncRNAs and nuclear 
receptors (or their genes) can affect receptor activity or expression.  Other lncRNAs function as 
downstream targets of the gene-regulating activities nuclear receptors.  Rosen and colleagues 
have identified pregnancy-induced noncoding RNA (PINC) as a lncRNA that is persistently up-
regulated in the involuted mammary glands of estrogen- and progesterone-treated rodents (Shore, 
Kabotyanski et al. 2012).  Although its function during early pregnancy is unclear, it may play a 
key role in regulating the development of lactating mammary glands.  The levels of the PINC 
transcript decline as mammary alveolar cells undergo terminal secretory differentiation.  In 
HC11 mouse mammary epithelial cells, PINC levels decreases upon lactogenic differentiation 
following hormone treatment.  Reduction in PINC levels enhances the lactogenic differentiation 
of HC11 cells, as shown in knockdown and overexpression experiments.  Mechanistically, PINC 
has been shown to interact with the chromatin-modifying PRC2 complex in RNA 
immumoprecipitation assays.  The PRC2 complex is also known to bind many other lncRNAs.  
In established molecular models, lncRNAs such as HOTAIR guide the PRC2 complex to its 
target genomic loci to exert epigenetic modification and transcriptional regulation (Fig. 3.2.5A).  
Whether PINC plays similar roles has yet to be determined. 
 Estrogen-regulated lncRNAs.  Global nuclear run-on and sequencing (GRO-seq) was 
recently used to explore the rapid effects of estrogen signaling on the entire transcriptome in 
MCF-7 human breast carcinoma cells, as well as identify thousands of novel estrogen-regulated 
ncRNAs, including lncRNAs(Hah, Danko et al. 2011).  Like some previously characterize 
estrogen-regulated protein coding genes, many estrogen-upregulated lncRNAs show estrogen-
induced ER binding in their proximal promoter regions, suggesting direct regulation by ER.  
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Those lncRNAs that show rapid and robust regulation in response to estrogen signaling are likely 
to play important roles in the estrogen signaling pathway.  Of course, further investigation is 
required to fully annotate and accurately determine the complete set of lncRNAs associated with 
the estrogen signaling pathway, as well as to functionally characterize the molecular mechanisms 
and biological roles played by these lncRNAs. 
lncRNAs regulating adipogenesis. By evaluating the differential expression of lncRNAs 
across primary brown and white adipocytes, preadipocytes, and cultured adipocytes, Sun and 
colleagues identified 175 lncRNAs that are specifically regulated during adipogenesis. Out of the 
175, they selected twenty lncRNAs that are likely regulated by PPARγ and CEBPα, the master 
regulators of adipogenesis, to perform a loss-of-function screen, from which they showed that 
ten of them function to modulate the progression of adipocyte differentiation(Sun, Goff et al. 
2013). The adipocyte is an active endocrine cell. Therefore, lncRNAs regulating adipocyte 
differentiation have important implications in endocrine-mediated metabolic functions.  
 
3.2.5. Conclusions and Perspectives 
The introduction of whole transcriptome sequencing methods, such as RNA-seq and 
GRO-seq, as well as the FANTOM and ENCODE transcript mapping projects, have transformed 
our perspectives on the variety and dynamic nature of lncRNAs.  A growing number of lncRNAs 
is being characterized and has been shown to play central roles in various biological processes, 
including cancer, metabolism, and endocrinology.  The list is growing with increasing interest 
and efforts in the field. 
Apart from broadening our perspectives on fundamental aspects of biology, lncRNAs 
offer possibilities in medicine.  Given their tissue-specific expression patterns, lncRNAs can be 
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superior biomarkers for certain diseases.  In the case of prostate cancer, PCA3 test has been 
developed and used clinically, utilizing the observation that the PCA3 lncRNA is specifically 
overexpressed in prostate cancer(Lee, Dobi et al. 2011).  Moreover, there is a transition from 
developing lncRNA-based diagnostics to exploring lncRNA-based therapies.  For example, 
antisense oligos (ASO) that attenuate the expression of MALAT1 in EBC-1 lung cancer cells 
inhibits metastasis to the lung(Gutschner, Hammerle et al. 2013).  While still in its infancy, the 
therapeutic promise of lncRNAs could be tremendous.  The growing interest in the identification 
and characterization of endocrine-associated lncRNAs could lead to new developments in the 
diagnostic, prognostic, and even therapeutics of endocrine diseases.  Nonetheless, a more 
thorough understanding of the biological functions of lncRNAs along with their detailed 
mechanisms of action, are required before we can fully exploit their potential utility.   
 Therefore, in the current study, I explored the implications of lncRNAs in breast cancer, 
which is another area where the clinical utility of lncRNAs is waiting to be exploited. There are 
already a number of lncRNAs, such as SRA, GAS5 and HOTAIR, that have been associated with 
the development and treatment outcomes of breast cancer. In addition, transcriptome analysis in 
MCF-7 breast cancer cells reported the abundance of lncRNAs and E2-regulated lncRNAs (Hah, 
Danko et al. 2011), hence raising the possibility that they are playing a previously under-
appreciated role in breast caner biology. In this study, I developed an integrative approach that 
incorporates the analysis of multiple high-throughput sequencing datasets and existing resources, 
to generate a comprehensive catalog of lncRNAs in basal and E2-stimulated MCF-7 cells. I 
revealed many interesting features of lncRNAs, and showed that the differential expression of 
lncRNAs predicts the intrinsic molecular subtype of breast cancer cells, suggesting their 
potential utility as prognostic biomarkers. Furthermore, by examining the tumor-specific 
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expression of lncRNAs and the “guilt-by-association” approach, I am able identify lncRNAs that 
are required for the normal growth of MCF-7 breast cancer cells. Whether these lncRNAs can 
potentially serve as new targets for therapeutic interventions will be the subject for future 
investigation. 
 
3.3. Results 
Integrative analysis of RNA-seq and GRO-seq generates a comprehensive catalog of lncRNA 
genes in MCF-7 cells 
To identify and annotate lncRNA genes in the estrogen-responsive MCF-7 human breast 
cancer cells, we developed a computational approach that incorporates evidence of RNA 
transcripts from multiple high-throughput sequencing datasets over a time course following 
treatments with E2. In brief, our pipeline consists of three major parts: (1) mapping and assembly 
of RNA transcripts from polyadenylated (polyA+) RNA-seq; (2) integration of nascent RNA 
profiles from GRO-seq; (3) processing and filtering of transcripts based on length, coverage, 
expression levels, and coding potential. Schematics and detailed steps of the analysis were 
illustrated in Fig. 3.3.1A and Fig. 3.3.2A. Sensitivity and specificity along the pipeline were 
reported in Fig. 3.3.2B. 
We sequenced polyA+ RNAs extracted from the whole cell, and from each of the 
cytoplasmic, nucleoplasmic and chromatin-associated fractions to evaluate mature RNA contents 
(Fig. 3.3.1C). Upon alignment to the reference human genome and transcript reconstruction as 
described previously (Cabili, Trapnell et al. 2011), we observed that cytoplasmic RNAs are more 
completely spliced, while RNAs in the nucleus often contain varying amounts of unspliced 
introns (Fig. 3.3.1D). It provides evidence for post-transcriptional splicing, and suggests that  
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Figure 3.3.1 Integrative analysis of RNA-seq and GRO-seq generates a comprehensive 
catalog of lncRNA genes in MCF-7 cells. 
 
(A) An overview of the experimental and analysis pipeline for the identification of lncRNA 
genes in MCF-7 cells (lncM).  
 
(B) The Venn diagrams show the fraction of lncM genes that are novel (red) and annotated 
(grey), and their overlap with annotations from RefSeq and GENCODE (orange), UCSC 
(purple), and lincRNA BodyMap (green) databases. 
 
(C) Western blotting shows the purity of the subcellular fractions used for RNA-seq. β-tubulin, 
SNRP70 and H3K4me3 are used as fraction-specific markers. 
 
(D) Genome browser view for the locus of an annotated lncRNA gene, CRNDE, showing 
RefSeq annotation, GRO-seq (blue) and fractionated RNA-seq (green) data. 
 
(E) Comparisons of mature transcript size distributions between lncRNA (blue) and protein-
coding genes (red) assembled from cytoplasmic RNA-seq data. 
 
(F) Cumulative distribution frequency curves show the sequence conservation of the promoters, 
exons and introns of lncRNA and protein-coding mRNAs assembled from cytoplasmic RNAs. 
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Figure 3.3.2 Generation of the lncRNA catalog. 
 
(A) The pipeline takes as inputs (left) polyadenylated RNA-seq data from total and fractionated, 
basal and E2-stimulated MCF-7 cells, existing coding annotation from RefSeq and GENCODE 
for humans, and previously available GRO-seq datasets across an estrogen treatment timecourse. 
RNA-seq data were aligned to the genome and assembled by Tophat and Cufflinks respectively. 
Cytoplasmic-based RNA-seq data (lncCYTO) were evaluated separately from nucleus-based 
RNA-seq (lncNR). Transcription units were called de novo from GRO-seq data using previously 
described methods. RNA transcripts with both RNA-seq and GRO-seq information were further 
filtered by coverage, size, and coding capabilities. The remaining transcripts pass through a 
FPKM threshold (>1) to derive at a set of 1888 expressed lncRNA genes (lncM).  
 
(B) Sensitivity and specificity at the base level measured by Cuffcompare, comparing transcripts 
from lncCYTO and lncNR at indicated points along the pipeline, lncM and lincRNA Bodymap 
annotations, to GENCODE lncRNA annotations. 
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mature RNA structures assembled based on the cytoplasmic RNAs will be more accurate. 
Therefore, we relied on cytoplasmic RNAs for the determination of exon-intron structure when 
possible, but also included transcripts that can only assembled from nuclear RNAs, to achieve a 
comprehensive list of lncRNAs. To capture the regulation of estrogens, we performed 
fractionation followed by RNA-seq in MCF-7 cells following 0 and 3 hours of E2 treatment. We 
also incorporated into our pipeline the nascent RNA profiles of these cells, as measured by GRO-
seq, with 0, 10, 25, 40 and 160 min. of E2 treatment, calling transcription units de novo as 
previously described (Danko, Hah et al. 2013), (Hah, Danko et al. 2011). It requires evidence of 
both mature and nascent RNAs to be included in our lncRNA catalog. 
Furthermore, lncRNAs in our catalog need to be reasonably “long”, most likely 
“noncoding” and reliably expressed. We applied the widely used length cutoff of 200 nt to multi-
exonic RNA transcripts. In the case of single-exonic transcripts, which are more susceptible to 
the limitations on the resolution of transcript assembly, a 1000-nt cutoff was used. To ensure the 
noncoding status of lncRNAs, we excluded transcripts with any overlap to known protein coding 
loci (RefSeq and GENCODE) running in the same direction, and eliminated transcripts scoring 
relatively high codon substitution frequency (i.e. phyloCSF score > 150) (Lin, Jungreis et al. 
2011), a bioinformatically computed measure of coding potential. All transcripts were required 
to pass a coverage threshold of 10 reads/base. Moreover, we calculated the steady state 
expression levels for the resulting lncRNA genes, as measured either by RNA-seq FPKM in the 
untreated whole cell, or by combined RNA-seq FPKM of the subcellular fractions in basal and 
E2-treated conditions (explained in later sections). Together, we collected an expressed set of 
1888 lncRNAs genes (lncM) with observed or combined RNA-seq FPKM > 1. Among the lncM 
genes, 42% (800) of them do not overlap with lncRNA genes annotated previously in RefSeq, 
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GENCODE, UCSC or lincRNA BodyMap databases (Fig. 3.3.1B) (Harrow, Denoeud et al. 
2006; Hsu, Kent et al. 2006; Cabili, Trapnell et al. 2011). They are novel lncRNAs first 
annotated in the current study. 
We focused on lncRNA genes assembled from cytoplasmic RNAs (lncCYTO, Fig. 
3.3.2A) for the examination of their gene structures, since they represent more accurate exon-
intron calls. Similar to what has been reported in the lncRNA study from the GENCODE project 
(Derrien, Johnson et al. 2012), the length of their mature transcripts is generally shorter, which 
can be attributed to the reduced number of exons per transcript (Fig. 3.3.1E). Also consistent 
with previous reports (Cabili, Trapnell et al. 2011; Derrien, Johnson et al. 2012), the underlying 
sequences of lncCYTO genes are evolutionarily less conserved compared to their protein-coding 
counterparts, yet they display local areas of modest conservation, as measured by the phastCons 
scores, in the exon and promoter regions relative to the intron regions (Fig. 3.3.1F).  
 
LncRNAs are only slightly enriched in the nuclear compartments, and nucleus-retained 
lncRNAs are less stable at steady state 
We compared the transcript abundance in each subcellular fraction of annotated protein-
coding mRNAs (codA) and lncRNAs (lncA), and lncM RNAs, and showed that regardless of 
where they are localized, lncRNAs are expressed at much lower steady-state levels than mRNAs 
(Fig. 3.3.3A, 3.3.4B). This difference could be partly attributed to the stability of the different 
types of transcripts. While lncRNAs are transcribed at similar levels, they appear to be less stable 
than the protein-coding mRNAs (Fig. 3.3.4A, C). We estimated the stability of RNA transcripts 
from the ratio of steady-state RNA level (RNA-seq FPKM) to nascent transcript level (GRO-seq  
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Figure 3.3.3 Subcellular localization of lncRNAs and protein-coding mRNAs. 
 
(A and B) Boxplots show (A) steady-state RNA levels in each of the subcellular fractions, and 
(B) the extent of nuclear localization, of codA (red), lncA (blue), and lncM transcripts (grey). 
 
(C) Tree diagram shows the significant ontological terms (red) associated with protein-coding 
mRNAs that are extracted from nuclear fractions. 
 
(D) Correlation of RNA stability measured by two independent approaches. Tani et. al. 
determined the half lives of RNA transcripts using BRIC-seq (vertical axis), and we estimated 
the stability of RNA transcripts based on the ratio of steady-state RNA levels to nascent 
transcript levels (horizonal axis). 
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Figure 3.3.4 Nuclear-retained lncRNAs are less stable than cytoplasmic lncRNAs. 
 
(A - C) Nascent transcript levels (A), steady-state RNA levels (B), and stability (C) of annotated 
protein-coding mRNAs (codA, red), annotated lncRNAs (lncA, blue) and lncM transcripts 
(grey). Stability of RNAs is measured by the ratio of steady-state RNA levels to nascent 
transcript levels. 
 
(D) Estimation of the contribution of each subcellular fraction to the total RNA content, based on 
the relationship a x Cyto +b x Nuc +c x Chrom = Total, where Cyto, Nuc, Chrom, and Total 
represent RNA-seq FPKM values from cytoplasmic, nucleoplasmic, chromatin-associated and 
whole cell samples, and a, b and c indicate their corresponding contributions. Pearson correlation 
coefficients were calculated and plotted for every pair of a x Cyto +b x Nuc +c x Chr and Total, 
calculated for all assembled transcripts, as we sample the proportion of each fraction, a (orange 
red), b (grey) and c (green) from 0.01 to 0.99. The combination, a = 0.5, b = 0.2, and c = 0.3 
gives the highest correlation and is highlighted in the plot. 
 
(E) Cumulative frequency curves show the extent of cytoplasmic localization of coda (red), lncA 
(blue) and lncM transcripts (grey and black), in basal (solid) and E2-treated (dotted) conditions.  
 
(F) Boxplot shows the stability of coda (red), lncA (blue) and lncM (grey) transcripts in basal 
MCF-7 cells, grouped by the extent of cytoplasmic localization.  
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RPKM), which correlates with the half times of RNAs measured by an independent method (Fig. 
3.3.3D) (Tani, Mizutani et al. 2012).  
Previous literature suggests that lncRNAs predominantly localize to the nucleus, and 
often get recruited to the chromatin to mediate epigenetic control and transcriptional regulation 
(Kapranov, Cheng et al. 2007; Mondal, Rasmussen et al. 2010; Derrien, Johnson et al. 2012). 
Nevertheless, a growing list of lncRNAs is found in the cytoplasm and characterized to be 
involved in cytoplasmic functions (Willingham, Orth et al. 2005; Gong and Maquat 2011; 
Carrieri, Cimatti et al. 2012; Clark, Johnston et al. 2012; Yoon, Abdelmohsen et al. 2012; Kretz, 
Siprashvili et al. 2013). In our pipeline, we are able to detect and annotate the majority of lncM 
genes, 800/1888, using RNA-seq reads obtained from the cytoplasmic fraction, which again 
raises the question to what extent lncRNAs are inside the nucleus and associated with the 
chromatin.   
To address this, we displayed the ratios of transcript abundance in the nuclear fractions 
over the cytoplasm in Fig. 3.3.3B, and observed that there is a slight but significant enrichment 
of the lncM RNAs, but not the previously annotated lncRNAs, relative to coding mRNAs in the 
nucleoplasm, and to a greater extent on the chromatin. Moreover, we estimated the contribution 
of each of the subcellular fractions to the total RNA pool as described in material and methods 
(Fig. 3.3.4D) to calculate the actual cytoplasmic content of every transcript, and we derived at 
the same conclusion that a smaller fraction of the lncM RNAs, in comparison to codA and lncA 
RNAs, are found in the cytoplasm (Fig. 3.3.4E). Nevertheless, our results support that in contrast 
to the traditional view, lncRNAs are only slightly enriched in the nuclear compartments. 
  114
When the codA, lncA and lncM transcripts were stratified into nuclear (< 30% 
cytoplasmic), intermediate, and cytoplasmic (>70% cytoplasmic), and their corresponding 
stability is displayed (Fig. 3.3.4F), we observed an interesting pattern that the nuclear lncRNAs 
are significantly less stable than the cytoplasmic lncRNAs. Indeed, a recent study that measured 
the half-life of about 100 mouse lncRNAs in a “stability microarray” has reached the same 
conclusion (Clark, Johnston et al. 2012). The authors have further speculated that this subset 
lncRNAs is turned over very rapidly to facilitate the dynamic regulation of cellular process in the 
nucleus. Moreover, our findings suggest that the lower stability of nuclear RNAs could be the 
reason for them to evade earlier annotation, and our approach takes advantage of its improved 
sensitivity in all subcellular fractions and allows for the identification of the less stable nuclear 
lncRNAs.  
 
Divergent and antisense lncRNAs are highly transcribed and contribute predominantly to the 
chromatin signatures associated with lncRNAs 
Historically, researchers have focused on lncRNAs that are well separated from existing 
coding loci, collectively known as long intergenic noncoding RNAs, or lincRNAs (Guttman, 
Amit et al. 2009; Khalil, Guttman et al. 2009; Guttman, Garber et al. 2010; Cabili, Trapnell et al. 
2011; Guttman, Donaghey et al. 2011; Ulitsky, Shkumatava et al. 2011). Nevertheless, the list of 
characterized natural antisense lncRNAs, those transcribed from the antisense strand and overlap 
in part with well-defined sense RNA transcripts, has been growing, some of them are involved in 
important cellular functions (Krystal, Armstrong et al. 1990; Munroe and Lazar 1991; Yan, Hong 
et al. 2005; Beltran, Puig et al. 2008; Carrieri, Cimatti et al. 2012). In addition, the phenomenon 
of divergent (bidirectional) transcription commonly occurs across the mammalian genome, 
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producing unstable transcripts that are likely lncRNAs (Core, Waterfall et al. 2008; Preker, 
Nielsen et al. 2008; Hah, Danko et al. 2011). Indeed, divergently transcribed lncRNA/mRNA 
gene pairs have been described in gene-specific and genomic studies (Rinn, Kertesz et al. 2007; 
Wang, Yang et al. 2011), the latter reporting varying degree of dominance as a group (Cabili, 
Trapnell et al. 2011; Sigova, Mullen et al. 2013). When we examined the distribution of lncM 
genes along the genome, we observed that about 21% of them are transcribed from the antisense 
strand, and overlap either the promoter (243 divergent lncRNAs) or the gene body (159 antisense 
lncRNAs) of a sense protein-coding mRNA or another lncRNA (Fig. 3.3.5A). To evaluate 
whether lncRNAs as a group favors the divergent and antisense arrangements, we examined the 
genomic distribution of codA genes. We found that the proportion of codA genes that overlap 
another coding locus, 15.1% divergent and 6.3% antisense, adds up to a similar fraction (data not 
shown). It suggests that similar to protein-coding genes, a considerable proportion of lncRNA 
genes originate from the genic regions.  
Moreover, we examined whether these genic lncRNA genes display any specific features 
that distinguish them from intergenic lncRNAs. Indeed, while the steady-state levels of lncRNAs 
appear comparable regardless of their gene location, divergent and antisense lncRNAs are more 
highly transcribed at the TSS and across the gene body as measured by GRO-seq (Fig. 3.3.5C, 
D), and it is likely contributed by their sense mRNA partner, which are often associated with the 
production of divergent transcripts even when an overlapping lncRNA is absent. 
Correspondingly, genic lncRNAs display much higher levels of H3K4me3, which marks active 
promoters, and H3K36me3, which is associated with actively elongating polymerases along the 
gene body than intergenic lncRNAs (Fig. 3.3.5C). Chromatin signatures are not strand specific. 
Therefore, most of the divergent RNA pairs share the same H3K4me3 domain, and antisense  
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Figure 3.3.5 Divergent and Antisense lncRNA genes are associated with higher levels of 
transcriptional activity and chromatin signatures. 
 
(A) Graphical representation of the orientation, position and length of antisense (top) and 
divergent (bottom) lncRNA genes (red) relative to their sense RNA genes (grey or blue).  
 
(B) Average profiles of GRO-seq reads (grey), and ChIP-seq reads of H3K4me3 (blue) and 
H3K36me3 (green), for codA (left) and lncM (right) genes. All gene bodies are scaled to 4 kb. 
ChIP-seq RPM of H3K36me3 are scaled to 3x its original value in order to show it clearly on the 
same plot. 
 
(C) Similar to (B), average profiles of GRO-seq reads, and ChIP-seq reads of H3K4me3 and 
H3K36me3, centered on the TSS of intergenic (Inter), antisense (AS), and divergent (Div) lncM 
genes.  
 
(D) Boxplot shows the steady-state RNA levels of Inter, AS and Div lncM genes.  
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lncRNA/mRNA pairs share at least a fraction of the H3K36me3 domain. The average gene 
profiles of transcription activity (GRO-seq) and chromatin signatures (H3K4me3 and 
H3K36me3) for lncM genes and codA genes share many similarities (Fig. 3.3.5B). Nevertheless, 
sense mRNAs with divergent or antisense lncRNAs on their opposite strand, likely contribute to 
the overall profile, and intergenic lncRNAs that are devoid of the influence of mRNAs show 
markedly lower level of transcriptional activity and its associated chromatin marks. 
 
LncRNAs display lower levels of promoter H3K4me3 and gene body H3K36me3 
Among the methods for the identification of lncRNA genes, the presence of H3K4me3-
H3K36me3 domain demarcates the location of the transcription units and is frequently used in 
previous studies (Guttman, Amit et al. 2009; Ulitsky, Shkumatava et al. 2011). Nevertheless, we 
observed very low levels of these marks associated with intergenic lncRNAs, where the 
influences of protein-coding genes are absent. It suggests that lncRNAs may be by nature 
displaying lower levels of these chromatin marks and hence questions the applicability of using 
these marks in identifying lncRNAs. 
To address this possibility, we focused on intergenic lncM genes and examined the levels 
of the associated H3K4me3 and H3K36me3 marks in comparison to codA genes that do not 
overlap with any antisense or divergent gene loci. Even when we controlled for the level of 
transcriptional activity, sampling codA genes that are transcribed at similar levels as lncM genes, 
they showed significantly lower levels of H3K4me3 at the TSS and H3K36me3 along the gene 
body (Fig. 3.3.6A). We then searched for additional properties that differs codA genes from 
lncM genes, such as their higher steady-state RNA levels, and asked whether it may be 
correlated with the observed differences in the levels of histone marks. Nevertheless, when we  
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Figure 3.3.6 Intergenic lncRNA genes display significantly lower levels of H3K4me3 at the 
promoter and H3K36me3 along the gene body than equally expressed protein-coding 
genes. 
 
(A and B) Boxplots comparing the levels of GRO-seq (orange) and H3K4me3 (blue) at the 
promoter, GRO-seq (orange) and H3K36me3 (green) along the gene body, and the steady-state 
RNA levels (grey) of selected codA genes with intergenic lncM genes. We sampled intergenic 
codA genes that have either the same distribution of GRO-seq levels at the promoter (A), or the 
same distribution of steady-state RNA levels (B), as indicated by the black bars.  
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controlled for the level of steady-state gene expression, lncM genes as a group still show much 
lower chromatin signatures than the sampled codA genes (Fig. 3.3.6B). In addition, we 
performed a similar analysis comparing coda genes with annotated intergenic lncRNAs (lncA), 
and the conclusion holds true (Fig. 3.3.7). We have also evaluated the contribution of the length 
of the transcript, the length of coding sequences and the number exons to the levels of H3K4me3 
and H3K36me3 marks associated with protein-coding genes, and it is apparent that these factors 
cannot sufficiently explain the significant differences in histone marks as we compare lncRNA to 
protein-coding genes (Fig. 3.3.8). 
In conclusion, intergenic lncRNAs that are devoid of the influences of coding mRNAs 
display lower levels promoter H3K4me3 and gene body H3K36me3, suggesting that using these 
marks to define the transcription units of intergenic lncRNAs likely suffer from this inherent 
limitation. 
 
ERα  localizes proximal to the promoters of E2-upregulated lncRNA genes, some of them are 
associated with an elevated level of enhancer features. 
It has been recently reported that E2 stimulation regulates an under-appreciated large 
fraction of the whole transcriptome, likely including the lncRNAs (Hah, Danko et al. 2011). 
Indeed, in the current study, we observed that more than a quarter (531 lncRNA genes, 28.1%) of 
the lncM genes are statistically regulated by E2. By comparing the regulation calls based on 
GRO-seq and RNA-seq datasets, we are able to distinguish regulation that occurs 
transcriptionally or post-transcriptionally (Fig. 3.3.9). At steady-state level, 158 lncRNA genes 
are upregulated, and 164 are downregulated. While half of the upregulated lncRNAs and a third 
of the downregulated lncRNAs show corresponding changes at nascent transcript level (Fig.  
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Figure 3.3.7 Intergenic lncA genes display significantly lower levels of H3K4me3 at the 
promoter and H3K36me3 along the gene body than equally expressed protein-coding 
genes. 
 
(A and B) Boxplots similar to Fig. 3.3.5, but comparing the levels of nascent transcription and 
chromatin signatures of selected codA genes with intergenic lncA genes. Two non-overlapping 
groups of codA genes were sampled, each having either the same distribution of GRO-seq levels 
at the promoter (A), or the same distribution of steady-state RNA levels with lncA genes (B). 
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Figure 3.3.8 Chromatin signatures of protein-coding genes are only minutely affected by 
the length of transcript, length of coding sequence (CDS) and the number of exons. 
 
(A - C) Boxplots show the levels of nascent transcription (GRO-seq) and chromatin signatures 
(H3K4me3, H3K36me3) of all codA genes, separated into lower quartile, interquartiles and 
upper quartile, based on the length of transcript (A), length of CDS (B), and number of exons 
(C). 
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Figure 3.3.9 LncRNA genes are regulated by E2 transcriptionally and post-
transcriptionally. 
 
(A and B) Boxplots showing E2-induced fold changes of lncM genes that are upregulated (A), 
and downregulated (B), at both transcriptional and steady-state RNA levels (left), at steady state 
only (middle), and at transcriptional level only (right). Red lines indicate the level where there is 
no fold change. 
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3.3.9A, B, left), the remaining ones are probably regulated by E2 post-transcriptionally (Fig. 
3.3.9A, B, right). On the other hand, there are also 375 lncRNA genes that are E2-regulated only 
at the transcriptional level. 66 of them are E2-induced (Fig. 3.3.9A, middle) and 209 of them are 
E2-repressed (Fig. 3.3.9B, middle), and they do not show statistically significant changes at 
steady-state level. Perhaps not surprisingly, lncRNAs with coordinated regulation at both levels 
are also associated with the highest degree of regulation, either up or down (Fig. 3.3.9A,B).  
Similar to protein-coding genes regulated by E2 at the transcriptional level, many E2-
regulated lncM genes show E2-induced ERα binding at their promoters as well. We measured 
the distance from the TSS of transcriptionally regulated lncRNA genes to their nearest ERα 
binding sites (ERBS) in the E2-treated condition, and observed a distinct segregation of E2-
upregulated lncRNA genes in close proximity to ERBS (Fig. 3.3.10A), suggesting that ERα is 
involved in the E2-induced transcriptional upregulation of these lncRNA genes.  
Moreover, lncRNA genes with ERα binding at their promoters remind us of a recent 
report on ERα enhancer RNAs (eRNAs) (Hah, Murakami et al. 2013), which are transiently-
expressed, short RNAs transcribed proximal to an ERBS. In addition, reports from the 
Shiekhattar lab have proposed an enhancer function for some of the lncRNAs, collectively 
known as ncRNA-activating (Orom, Derrien et al. 2010). Together, it raises the question of 
whether lncRNAs and eRNAs are distinct concepts. Therefore, we closely examined the profile 
of H3K4me1, a commonly used histone mark to define enhancers, and of H3K4me3, a mark of 
active gene promoter, at the promoter of lncM genes, in comparison to previously defined 
eRNAs (Hah, Murakami et al. 2013). We observed that lncM genes that display promoter 
proximal ERα binding in the E2-treated condition are associated with a comparable level of 
H3K4me1 to the promoter of eRNAs (Fig. 3.3.10B, C). When we compared the profiles of  
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Figure 3.3.10 ERα  localizes to the promoters of a subset of lncRNA genes, which are 
associated with an elevated level of enhancer features. 
 
(A) Graphical representation of the length and distance from the nearest ERα-binding site 
(ERBS) of transcriptional regulated lncM genes. 
 
(B) Boxplots comparing the levels of ERα, as well as enhancer (H3K4me1) and promoter 
signatures (H3K4me3) at promoter regions of codA genes (red) and eRNAs (yellow) with 
promoter proximal ERα binding, and of lncM genes with (blue) and without proximal ERα 
binding (light blue).  
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promoter signature, ERα-bound lncM genes show an intermediate level of H3K4me3 in 
comparison to ERα-bound eRNAs and protein-coding genes (Fig. 3.3.10C). Therefore, a subset 
of lncRNA genes are associated with promoter proximal ERα binding and an elevated level of 
enhancer features. 
 
LncRNAs carry important cellular information and the cell type-specific expression of 
lncRNAs predict the intrinsic molecular subtype of breast cancer cells 
As we examined the differential expression of lncRNA and protein-coding genes across a 
panel of 304 samples encompassing a whole spectrum of cancer and normal tissue samples and 
cell lines, our results agreed with a previous report (Cabili, Trapnell et al. 2011) that lncRNAs 
show more tissue- and cell type-specific expression than protein-coding mRNAs (Fig. 3.3.11A). 
The differential expression of protein-coding genes has been reasonably explored by researchers 
for its utility in the clinics as diagnostic and prognostic biomarkers (Alizadeh, Eisen et al. 2000; 
Perou, Sorlie et al. 2000; Nielsen, West et al. 2002), such as in the case of using PAM50 to 
subtype breast cancers into their intrinsic molecular subtypes that are associated with different 
prognostic outcomes (Parker, Mullins et al. 2009). The expanding landscape of lncRNAs is a 
relatively untouched ground, and their tissue- and cell type-specific expression patterns make 
them highly attractive as new and alternative biomarkers. Indeed, the differential expression of 
lncRNAs allowed them to accurately cluster the hundreds of samples into their respective tissue 
types in an unsupervised manner (Fig. 3.3.11B). More interestingly, they are able predict the 
intrinsic molecular subtypes of a panel of 45 human breast cancer cell lines, to a similar accuracy 
as the performance of protein-coding genes (Fig. 3.3.11C), suggesting that they carry a similar 
amount of important cellular information. Therefore, lncRNAs, or a selected subset of them, or  
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Figure 3.3.11 Tissue- and cell type-specific expression of lncRNA genes informs tissue 
identity and predicts the intrinsic molecular subtype of breast cancer cells. 
 
(A) Density plot shows the breadth of expression of lncM (blue) and protein-coding genes (red) 
across a panel of 304 tissue samples and cell types. 
 
(B) Hierarchical clustering of 150 tissue samples from ten different tissues/organs of origin, 
including tumor (solid circle) and benign (open circle) samples, based on the differential 
expression of lncM genes. 
 
(C) Hierarchical clustering of 45 breast cancer cell lines into their instinct molecular subtypes, 
basal (B), claudin-low (CL), and luminal (L), based on the differential expression of lncM genes. 
Mis-classified cell lines are shown in red. 
 
(D) Boxplots show examples of lncRNA genes with elevated expression in breast tumors (T, red) 
in comparison to benign breast tissues (B, grey). HOTAIR and PVT1 are previously characterized 
lncRNAs that have been implicated in breast cancer. LOC145837 (R152) is an uncharacterized 
lncRNA that we picked for subsequent study. The expression of R152 (LOC145837) is cancer-
specific and subtype-specific, showing elevated levels in luminal (L, orange) and basal (B, 
green) breast cancer cells.  
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the combined use of selected lncRNAs together with additional protein-coding genes, could 
potentially serve as new and improved prognostic biomarkers in predicting the treatment 
outcomes for breast cancer. 
 
LncRNAs are required for the normal growth of MCF-7 human breast cancer cells  
We have identified and annotated a comprehensive catalog of lncRNA genes in MCF-7 
breast cancer cells, and close examination of these lncRNAs revealed many interesting features. 
Moreover, we want to characterize the molecular and functional roles of lncRNAs in human 
breast cancer cells, so as to fully appreciate their implications in breast cancer.  
As mentioned earlier, we evaluated the differential expression of lncRNAs across a whole panel 
of cancer and normal tissue samples and cell lines, including 12 breast tumor samples and 11 
benign breast samples. It is reasonable to hypothesize that lncRNAs with elevated expression in 
breast tumors are more likely implicated in breast cancer. Indeed, when comparing the 
expression of each lncRNA across breast tumor samples in comparison to that across benign 
samples, and selecting for ones with cancer-specific expression, HOTAIR and PVT1, two 
previously characterized lncRNAs that are associated with the development of breast cancer, are 
among the top hits (Fig. 3.3.11D, top). Therefore, we returned to the list of lncRNAs with breast 
cancer-specific expression, and focused on R152 (LOC145837), a previously uncharacterized 
lncRNA that shows luminal- and basal-specific expression in human breast cancer cells (Fig. 
3.3.11D, bottom), and asked if it also mediate important functional roles in MCF-7 cells, a 
luminal breast cancer cell line. Indeed, the expression of R152 is required for the normal growth 
of MCF-7 cells, validated using two independent siRNA oligos (Fig. 3.3.12B). 
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Figure 3.3.12  LncRNAs are required for the normal growth of MCF-7 breast cancer cells. 
 
(A) List of the top 10 REACTOME pathways from the “guilt-by-association” analysis performed 
on lncRNA R67, as described in materials and methods. 
 
(B) siRNA-mediated knockdown of lncRNA R152, using two independent siRNA oligos, si152-
1 (red), and si152-2 (green). (Left) Analysis of R152 expression by RT-qPCR. β-action was used 
as an internal control. Each bar represents mean + SEM, n=3. (Right)  Analysis of basal cell 
growth in control (siCtrl) and R152 knockdown MCF-7 cells, over a course of 6 days post-
transfection of siRNAs. Each point represents mean ± SEM, n=3.  
 
(C) Similar to (B), siRNA-mediated knockdown of R67 by two independent oligos, si67-1 
(orange), and si67-2 (blue), and its effects on basal cell growth in MCF-7 cells. 
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In addition, we searched for genomic methods that would provide some clues to the 
possible functions of more lncRNAs. One of the more commonly used ones is the “guilt-by-
association” approach as described in materials and methods. In brief, it relies on the correlation 
relationships between uncharacterized lncRNAs and protein-coding genes of known function, 
hence linking the functional pathways associated with the most highly correlated proteins to the 
lncRNA of interest. Therefore, we performed the “guilt-by-association” analysis on lncRNAs 
and selected candidates that are associated with important cell viability pathways. For example, 
Fig. 3.3.12A lists the top 10 REACTOME pathways that are most enriched in the analysis 
performed on the lncRNA R67, most of these pathways are related to the control of cell cycle. 
Consistently, we observed a corresponding inhibition of cell growth as we knocked down the 
expression of R67 in MCF-7 cells using two independent siRNA oligos (Fig. 3.3.12C). 
Therefore, we have shown two examples of lncRNAs, R152 and R67, that are required for the 
normal growth of MCF-7 cells. Future studies will reveal their functional interplay with the 
estrogen signaling pathway in E2-responsive breast cancer cells, whether they are also involved 
in cell growth responses in other breast cancer cell lines, and the molecular mechanisms 
underlying the observed inhibitory effects on cell growth, so as to ultimately establish a role for 
these lncRNAs in breast cancer biology and to raise the possibility of using lncRNAs as new 
therapeutic targets. 
 
3.4. Discussion 
In this study, we have generated the most comprehensive catalog of lncRNAs in MCF-7 
human breast cancer cells, capturing lncRNAs that are expressed across an estrogen treatment 
time course, and localize to all three subcellular compartments. In addition to previously 
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annotated lncRNAs, we have identified ~800 novel lncRNA genes expressed in MCF-7 cells. 
Moreover, we annotated the exon-intron structure of these lncRNAs with the best-available 
knowledge, giving preference to transcript assembly performed on cytoplasmic RNAs. We then 
examined all lncRNAs (lncM) as a group, and revealed many interesting findings that are 
relevant for future efforts in the identification and annotation of lncRNAs. 
Our results have raised concerns for the utility of H3K4me3-H3K36me3 domains in the 
discovery of lncRNAs, as we observed that majority of lncRNA genes are not associated with 
high levels of H3K4me3 and H3K36me3. The lower than expected level of chromatin signatures 
cannot be fully explained by the level of transcription, level of steady-state RNA, length of 
transcript and the number of exons. Therefore, using H3K4me3-H3K36me3 to define the 
genomic location of lncRNA genes will likely suffer from low sensitivity, and will be biased 
towards the discovery of divergent lncRNAs, which likely carry over some influences from the 
sense mRNAs. On the other hand, we have demonstrated the better performance of using GRO-
seq results to capture the location and activity of the primary transcripts of lncRNA genes. In 
many cases, even with lower steady-state RNA level, and lower chromatin signatures, most 
lncRNAs show comparable nascent transcript level as measured by GRO-seq in comparison to 
their protein-coding counterparts. 
In addition, contrary to common belief, lncRNAs are trafficked to all subcellular 
compartments, and there is only a slight enrichment in the nucleus. Nevertheless, others and we 
have independently demonstrated that lncRNAs in the nucleus tend to be less stable (Clark, 
Johnston et al. 2012), and are more likely to evade detection. Therefore, efforts should not be 
focused solely on nucleus-localized lncRNAs and their associated nuclear functions, as 
cytoplasmic lncRNAs form the other abundant class with a whole spectrum of new possibilities, 
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as in the case of lincRNA-p21 and TINCR (Yoon, Abdelmohsen et al. 2012; Kretz, Siprashvili et 
al. 2013). Nevertheless, it is reasonable to come up with more sensitive ways to detect lncRNAs 
in the nucleus, and the use of fractionated RNA-seq in the current study is one such example, as 
there may exist transiently expressed nuclear lncRNAs that are involved in the dynamic 
regulation of time-sensitive events, but have evaded earlier detection efforts due to their transient 
nature. 
Furthermore, the observed subcellular localization of lncRNAs raises two interesting 
questions for future study. (1) Trafficking of proteins can be driven by peptide signals, such as a 
nuclear localization signal, or NLS, which is encoded in the amino acid sequence of the 
trafficked proteins. What drives the subcellular localization of lncRNAs? (2) The observed lower 
stability of lncRNAs and the even lower stability associated with the nuclear lncRNAs are 
properties that are distinct from protein-coding mRNAs. It suggests a different mechanism in the 
regulation of stability and degradation. Which factors are involved in this lncRNA-specific 
regulatory pathway? Answers to these questions will expand our knowledge in the biochemistry 
and molecular biology of lncRNAs, and in RNA biology in general. 
Moreover, we have identified a significant fraction (28.1%) of lncRNA genes that are 
regulated by E2. The estrogen signaling pathway gets initiated, and triggers a profound and 
coordinated network of gene regulation involving almost all types of RNA transcripts (Hah, 
Danko et al. 2011), both transcriptionally and post-transcriptionally. Here, we are able to 
distinguish lncRNAs that are only regulated at the transcriptional level from those that are 
regulated by steady-state level. In a model that E2-regulated lncRNAs are integral players in the 
estrogen signaling pathway, we can speculate a scenario where some of them respond to E2 
stimulation and result in altered levels of steady-state RNAs to directly modulate E2-dependent 
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cellular outcomes, while others are only transcriptionally regulated and may act as enhancers to 
coordinate the steady-state expression of other lncRNAs and mRNAs that may directly impact in 
the estrogen signaling pathway. 
Indeed, lncRNA genes with ERα binding at their promoters show an elevated level of 
enhancer mark, H3K4me1, which is comparable to the H3K4me1 profile of the recently 
characterized eRNAs (Hah and Murakami et al. 2013). Perhaps, a subset of these lncRNAs 
originate from a distinct class of enhancers, and form a distinct class of eRNAs, to perform 
enhancer functions as suggested by Lai and colleagues (Lai, Orom et al. 2013). Whether this 
model holds true will be the subject of future studies. 
In agreement with previous findings, we have shown that lncRNAs demonstrate tissue- 
and cell type-specific expression in comparison to protein-coding genes. More importantly, the 
differential expression of lncRNAs carry useful information associated with the tissue and cell 
identity, and is able to classify breast cancer cells into their intrinsic molecular subtypes, 
suggesting its potential utility as prognostic biomarkers in real breast cancer patients. Future 
studies are required to select the optimal and minimal subset of lncRNA genes for this purpose, 
and to compare its efficacy with currently available methods. 
Moreover, the exploration of the utility of lncRNAs does not stop at the prognostics. 
Ultimately, we wish to elucidate the molecular and functional roles of lncRNAs in human breast 
cancer cells so as to generate new targets for therapeutic interventions in treating breast cancer, 
and this has been an area with great challenges. In this study, we focused one lncRNA gene 
(R152) that shows elevated expression in breast tumors in comparison to benign tissues, and 
another one (R67) that is associated with important cell viability pathway from the “guilt-by-
association” analysis, and demonstrated that they are required for the normal proliferation of 
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MCF-7 breast caner cells. While the molecular details associated with these two lncRNAs need 
to be further elucidated, the cancer-specific lncRNA R152 shows great promises as a new drug 
target. Clearly, a few lncRNAs, including the previously characterized HOTAIR, GAS5, SRA 
and PVT1, as well as the newly characterized R152 and R67, have been shown to play key roles 
in important cellular processes in breast cancer, the jury is still out regarding the implications of 
lncRNAs as a group. Just like many previous lncRNA studies, we have generated many answers, 
as well as many more questions that need to be addressed in future studies.  
 
3.5. Materials and Methods 
Cell culture and treatments.  MCF-7 cells were maintained in MEM with Hank’s salts (Sigma; 
M1018) supplemented with 5% calf serum.  For experiments involving estrogen treatment, the 
cells were grown for at least 3 days in phenol red-free MEM Eagle medium with Earle's salts 
(Sigma; M3024) supplemented with 5% charcoal-dextran-treated calf serum, and treated with 
ethanol (vehicle) or E2 (100 nM) for the times specified in the figure legends.   
 
Cell fractionation.  Estrogen-starved MCF-7 cells were treated with ethanol or 100 nM E2 for 45 
min. Two biological replicates of 107 cells were processed for each experimental condition. They 
were trypsinized and collected, and subsequently lysed in buffer A (0.01 M HEPES pH 7.6, 0.01 
M KCl, 15 mM MgCl2, 0.34 M sucrose, 10 % glycerol, 1mM DTT, 0.3 mg/ml digitonin) in the 
presence of proteinase and RNase inhibitors. The soluble extract represented the cytoplasmic 
fraction. The remainder was then washed twice with buffer A, each time accompanied by 10 
strokes of douncing, to obtain clean and intact nuclei. The nuclei were then ruptured with the 
sequential addition of low salt buffer (0.02 M Tris-HCl pH 7.5, 0.02 M KCl, 15 mM MgCl2, 0.2 
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mM EDTA, 25 % glycerol) and high salt buffer (low salt buffer with 1.2 M KCl) in the presence 
of proteinase and RNase inhibitors to extract the nucleoplasmic contents into the soluble fraction. 
The insoluble pellet was then resuspended in cell disruption buffer (PARIS kit, Ambion), 
digested with DNase I (Roche), and taken as the chromatin-associated fraction. Total RNAs were 
extracted from each of the fractions using the PARIS columns (Ambion). They were further 
processed for whole genome polyadenylated RNA sequencing (poly(A)+ RNA-seq) as described 
below. In addition, the fractionated extracts were subjected to immunoblotting using antibodies 
against the cytoplasmic marker β-tubulin (Abcam, ab6046), the nucleoplasmic marker SNRP70 
(Abcam, ab83306), and the chromatin-associated marker histone H3K4me3 (Active Motif, pAb), 
for confirmation of the purity of the subcellular fractions.  
 
Poly(A)+ RNA-seq. Total RNAs from subcellular fractions were isolated as described above. 
Total RNAs from unfractionated MCF-7 cells were isolated using the RNeasy kit (QIAgen). 
Poly(A)+ RNAs were purified from these samples using Dynabeads® Oligo(dT)25 (Invitrogen) 
as described previously (Zhong, Joung et al. 2011). Strand-specific libraries were prepared 
according to the “deoxyuridine triphosphate (dUTP)” method described in the same protocol. An 
Illumina HiSeq 2000 was used for sequencing with a single-endsequencing length of 50 nt for 
the unfractionated poly(A)+ RNA-seq sample and a paired-endsequencing length of 100 nt for 
the treated and fractionated poly(A)+ RNA-seq samples. 
 
LncRNA annotation pipeline.  
a. RNA-seq read mapping. All paired-end RNA-seq reads generated, one replicate from 
untreated MCF-7 cells and two biological replicates each from the fractionated and vehicle- or 
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E2-treated cells, were aligned to the human genome (NCBI 37, Hg19) using the spliced read 
aligner TopHat version V2.0.4 (Kim, Pertea et al. 2013). For this analysis, we used two iterations 
of Tophat alignments as previously suggested (Cabili, Trapnell et al. 2011), to maximize the use 
of splice site information derived across all samples. Reads from all samples were first aligned 
with the purpose of splice-junction discovery, by not supplying any annotation files and 
including the “min-anchor-length” and “microexon-search” parameters. We then pooled the 
predicted splice sites across all alignments, and used the pooled junction file to facilitate the re-
alignment of each of the fractionated RNA samples with the “raw-juncs” and “no-novel-juncs” 
parameters.  
 
b. Transcriptome assembly. The biological replicates were combined and the transcriptome for 
each subcellular fraction and each treatment condition was then assembled by Cufflinks version 
V2.0.2 (Trapnell, Williams et al. 2010). After obtaining six unique sets of assembled isoforms, a 
minimal read coverage threshold and size selection filters were applied.  
Minimal read coverage threshold. We ran Cufflinks with its transcript abundance calculation 
mode to estimate the read coverage of each transcript, and we removed transcripts with a 
maximal coverage below 10 reads per base. 
Size selection. lncRNAs are mostly defined to be longer than 200 bp, therefore, we excluded 
multi-exonic transcripts smaller than 200 bp. We also considered the limitation of cufflinks in 
resolving the start and stop site of each transcript, and applied a more stringent size threshold of 
1 kb to single exon transcripts. 
The filtered transcripts were then merged into two sets using Cuffmerge, the cytoplasmic set and 
the nucleus-localized set containing both the nucleoplasmic and chromatin-associated fractions. 
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In addition, we removed any transcripts from the nucleus-localized set that overlaps with 
transcripts from the cytoplasmic set, to obtain two distinct sets of transcripts. 
 
c. Filter of known non-lncRNA annotations. In both sets of transcripts, we eliminated those that 
had an exon overlapping a transcript from either coding genes annotated in RefSeq or in 
GENCODE V12. Single-exonic transcripts that trail behind and are within 2000 bp of an 
annotated coding gene were also removed, as they may represent polymerase run-on fragments 
of the coding gene. In addition, we classified each transcript based on its relative location with 
respect to its nearby coding gene, into divergent, antisense or intergenic. 
 
d. Filter of transcripts lacking primary transcript evidence. GRO-seq data sets in MCF-7 cells, 
following 0 to 40 min. of E2 treatment, were obtained from earlier work in the Kraus Lab. They 
were re-analyzed to provide evidence of primary transcripts for potential lncRNA genes. As 
previously described, GRO-seq data were aligned to hg19 using SOAP2, and uniquely mappable 
reads were converted into bigWig files for visualization in UCSC genome browser, and into R 
data files for subsequent analysis. We called transcripts de novo based on a two-state Hidden 
Markov model, using the GRO-seq data analysis package (Hah, Danko et al. 2011). We then 
compared the filtered transcripts assembled from RNA-seq experiments to transcripts being 
called from the GRO-seq data, and retained only those that present evidence at both RNA-seq 
and GRO-seq levels. 
 
e. Positive coding potential threshold. We estimated for each transcript the coding potential, as 
measured by codon substitution frequency (CSF), or the degree of evolutionary pressure in 
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maintaining the signature of an open reading frame against random substitutions. We ran 
PhyloCSF using a multiple sequence alignment of 29 mammalian genomes, 
(http://hgdownload.soe.ucsc.edu/goldenPath/hg19/multiz46way/) to obtain the best scoring open 
reading frame across all three reading frames. We excluded from our lncRNA catalog all 
transcripts with a PhyloCSF score greater than 150. This PhyloCSF threshold is determined by 
optimizing the sensitivity and specificity in correctly classifying RefSeq annotated protein-
coding and noncoding transcripts, and it corresponds to a false discovery rate of 9 % for coding 
genes and false positive rate of 12 % for noncoding genes. 
 
f. Transcript abundance threshold. We obtained transcript abundance, in terms of FPKM, for all 
transcripts by running Cufflinks. A FPKM threshold of 1 was applied to all lncRNA transcripts 
for most of the bioinformatics analysis in this study to only characterize those transcripts that 
were reasonably expressed in MCF-7 cells under our experimental conditions. 
 
Sequence conservation estimation. For each lncRNA or protein-coding transcript, sequence 
conservation levels of the exons, introns and promoters were measured by the phastCons scores, 
which were extracted from the vertebrate phastCons elements 46-way table (UCSC table 
browser, comparative genomics, conservation tracks). We set the regions 1 kb upstream the 
transcription start site (TSS) as promoters. 
 
Chromatin signatures. ChIP-seq data sets for H3K4me3, H3K36me3, H3K4me1, H3K27ac, 
ERα, CBP, SRC2, FOXA1 and AP2γ in either untreated, vehicle- or E2- treated conditions were 
obtained from various sources as listed in Supplementary Table 1. They were aligned to hg19 
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using Bowtie (Langmead, Trapnell et al. 2009), and uniquely mappable reads were converted 
into R data files for subsequent analysis. We then took processed data from both GRO-seq and 
ChIP-seq to delineate chromatin signatures around specified regions. Metagenes were used to 
illustrate the distribution of GRO-seq and ChIP-seq reads around the specified regions, using the 
metagene function in the GRO-seq data analysis package (Hah, Danko et al. 2011). Boxplots 
representations were used to minimize the bias caused by outliers in the data, which can lead to 
inaccurate interpretation of metagene representations. The read distribution in a given region was 
calculated and plotted using the boxplot function in R. 
 
Estimation of subcellular distribution. To estimate the contribution of each subcellular fraction 
to the total population of poly(A)+ RNA, we utilize the relationship a x Cyto +b x Nuc +c x Chr 
= Total, where Cyto, Nuc, Chr and Total refer to the FPKM values of each transcript in 
cytoplasmic, nucleoplasmic, chromatin-associated and total poly(A)+ RNA-seq samples 
respectively, and a, b and c indicate their corresponding contributions. We sampled the values of 
a, b and c from 0.01 to 0.99, and calculated the corresponding values of estimated total FPKM, a 
x Cyto +b x Nuc +c x Chr, and the observed total FPKM, Total, for each of the Cufflinks-
assembled transcript. We then performed a Kolmogorov–Smirnov (KS) test and calculated the 
Pearson correlation coefficient between the estimated and the observed total FPKM. The set of a, 
b and c that yield significant KS p-values and highest correlation coefficients represent the 
estimated contribution of subcellular fractions. 
 
Estimation of transcript stability. To obtain a simple and convenient measure of transcript 
stability, we calculated the ratio of RNA-seq FPKM over GRO-seq RPKM for each lncRNA and 
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mRNA transcript, as it reflects the relative abundance of the mature RNA transcript over its 
corresponding primary transcript. 
 
Determination of regulation at transcriptional level and steady-state RNA level. 
Transcriptional regulation was determined from GRO-seq reads using the bioconductor package 
edgeR as previously described, and we applied a 5% false discovery rate (FDR) to the analysis. 
Regulation at steady state RNA level was determined from RNA-seq reads using Cuffdiff, also 
with a 5% FDR.    
 
Breadth and specificity of lncRNA and mRNA expression. Unstranded poly(A)+ RNA-seq 
datasets from 135 tumour tissues, 27 benign tissues, 109 tumour cell lines and 22 benign cell 
lines of the breast, prostate, stomach, malenocytes, pancreas, bladder, kidney, salivary gland, 
lymphoid and myeloid tissue were obtained from the Michigan Center for Translational 
Pathology (Kalyana-Sundaram, Kumar-Sinha et al. 2012). RNA-seq data from 3 additional 
breast cancer cell lines and 8 benign breast tissue samples were obtained from the Mayo Clinic 
(Asmann, Hossain et al. 2011). These RNA-seq results were mapped using Tophat and 
assembled in a similar manner as the newly generated RNA-seq datasets in MCF-7 cells using 
Cufflinks, which also generates the expression of all lncRNAs and mRNAs in terms of FPKM. A 
FPKM cutoff of 1 was applied to determine if a given lncRNA or mRNA is expressed in any 
particular tissue sample or cell line. Hierarchical clustering was performed on the differential 
expression of lncRNAs across all tissue samples and all breast cancer cell lines to evaluate its 
ability in predicting tissue identity and the intrinsic molecular subtype of breast cancer cells 
respectively. 
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Guilt-by-Association Analysis. The expression level of each lncRNA across the panel of 304 
tissues and cell lines was correlated with all protein-coding genes. Each lncRNA was then 
associated with the entire list of protein-coding genes, ranked by their correlation with the 
lncRNA. We ran gene set enrichment analysis (GSEA), using the curated gene sets of canonical 
pathways and oncogenic signatures, on the ranked list of protein-coding genes to indentify 
pathways and signatures that are significantly enriched for the particular lncRNA. 
 
Knockdown of lncRNAs in MCF-7 cells. Transient RNAi-mediated knockdown of lncRNAs 
was performed using transient transfection of siRNAs targeting lncRNAs and a control siRNA 
purchased from Sigma. The siRNA oligos was transfected into MCF-7 cells using the 
Lipofectamine RNAiMAX reagent following the manufactures’ protocol. Forty-eight hours post 
transfections, the cells were collected for the evaluation of the efficiency of knockdown using 
RT-qPCR. 
 
Proliferation Assay. After indicated days post-transfection, MCF-7 cells were fixed with 10% 
formaldehyde, stained with 0.1% of Crystal Violet, and subsequently washed and detained with 
10% acetic acid. The acetic acid was then collected and red at absorbance 595nm to record the 
relative cell growth. 
 
Analysis of lncRNAs and mRNAs by RT-qPCR. RT-qPCR detection of lncRNAs and mRNAs 
were performed as described previously. Total RNA was isolated from the cells using Trizol 
(Invitrogen) followed by isopropanol precipitation. It was then subjected to RT using oligoDT 
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(dT22) and MMLV Reverse transcriptase (Promega). The cDNA was then subjected to qPCR 
analysis using a Roche LightCycler 480 system with SYBR Green detection and gene-specific 
primers. Gene-specific primers used in this study were listed in Supplementary Table 3. Each 
experiment was performed a minimum of three times with independent biological samples to 
ensure reproducibility. 
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